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Abstract 
 
The application of naked DNA instead of therapeutic proteins has become a main 
subject of medical investigation. The development of new therapeutic methods like 
gene therapy and DNA vaccination has caused a growing demand for high quality 
plasmid DNA (pDNA). 
For an optimal yield of pDNA, it is important to be able to regulate plasmid copy 
number (PCN) as extensive plasmid replication exerts metabolic burden on the host 
cell, and as a consequence leads to growth cessation.  
 
In this work, control of PCN of ColE1-type plasmids should be achieved by RNA-RNA 
interaction as well as by RNA-tRNA interaction. 
In a first approach the RNAI-gene was inserted into the E.coli chromosome and put 
under the control of the T7 promoter. By the addition of isopropyl-beta-D-
thiogalactopyranoside (IPTG), RNAI-expression was induced in shake flask 
experiments and the influence on different ColE1-type plasmids was followed. It 
could be shown that extensive RNAI expression resulted in a dramatic decrease of 
PCN. As this effect was also observed in the case of no IPTG addition the leaky T7-
system was exchanged by the pLlacO-1 promoter. By the use of this promoter, RNAI 
expression was restricted to IPTG addition.  
 
In a second approach regulation of PCN should be achieved by tRNA over 
expression. It was reported recently, that uncharged tRNAs can interact with RNAI, 
thereby mediating cleavage of RNAI. Reduction of functional RNAI should further 
lead to an increase in the number of uninhibited RNAII molecules and thus, in 
enhanced initiation of plasmid replication. Therefore, a chromosomal copy of the 
tRNAAla-gene was brought under the control of the T7 promoter. Because of two point 
mutations charging of tRNA molecules was inhibited. Expression was again induced 
by the addition of IPTG in shake flask experiments and PCN of ColE1-type plasmids 
was determined.  
 
With this work it could be demonstrated, that PCN of ColE1-type plasmids can be 
regulated and reduced, respectively by the expression of a chromosomal copy of the 
RNAI-gene under the control of the pLlacO-1 promoter. The over expression of 
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uncharged tRNAs however, showed an unexpected effect. Contrary to publications, 
predicting an increase in plasmid replication, expression of tRNA led to a clear 
reduction of PCN.  
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Zusammenfassung 
 
Die therapeutische Verwendung von DNA anstelle von Proteinen ist zu einem 
bedeutenden Gegenstand medizinischer Forschung geworden. Die Entwicklung 
neuer Therapieformen wie der Gentherapie und DNA-Impfstoffen hat den Bedarf an 
hochwertiger Plasmid-DNA stark gesteigert. Die Regulation der Plasmidkopienzahl 
(PCN) ist dabei für eine optimale DNA-Ausbeute ausschlaggebend. Eine zu starke 
Plasmidreplikation würde nämlich zu einer Überlastung und schließlich zum 
Zusammenbruch des bakteriellen Stoffwechsels führen.  
 
Gegenstand dieser Arbeit war es die Replikation von Plasmiden mit ColE1-ori mittels 
RNA-RNA-Interaktion sowie tRNA-RNA-Wechselwirkung regulierbar zu machen. 
Dazu wurde in einem ersten Schritt das RNAI-Gen unter der Kontrolle des T7-
Promotors ins bakterielle Escherichia coli (E.coli) Genom integriert. In 
Schüttelkolbenversuchen wurde anschließend die RNAI-Expression durch die 
Zugabe von Isopropyl-β-D-thiogalactopyranosid (IPTG) induziert und ihre Auswirkung 
auf die Replikation verschiedener ColE1-Plasmide untersucht. Es konnte gezeigt 
werden, dass die Überexpression von RNAI zu einer starken Reduktion der PCN 
führt. Da es sich beim T7-System allerdings um ein sehr undichtes handelt, wurde 
dieser Effekt auch im uninduzierten Zustand sichtbar. Deshalb wurde der T7-
Promotor in einem weiteren Schritt durch den pLlacO-1 Promotor ersetzt wodurch eine 
regulierbare RNAI-Expression möglich wurde. Nur im Fall der Induktion durch IPTG 
wurde die PCN gesenkt.  
In einem weiteren Ansatz wurde versucht die Plasmidreplikation durch die 
Überexpression von unbeladenen tRNAs zu steigern. Dazu wurde das tRNAAla-Gen 
unter die Kontrolle des T7-Promotors gebracht und wiederum ins E.coli Genom 
integriert. Zwei Punktmutationen in diesem Gen verhinderten dabei die Beladung der 
tRNA-Moleküle mit Alanin. Auch in diesem Fall wurde die Genexpression in 
Schüttelkolbenversuchen durch die Zugabe von IPTG induzierte, und deren 
Auswirkung auf die Replikation von ColE1-Plasmiden untersucht. Laut bereits 
existierenden Publikationen, sollte es zur Wechselwirkung zwischen unbeladener 
tRNA und RNAI kommen. Der daraus resultierende Anstieg an freier RNAII sollte in 
weiterer Folge zu einer Erhöhung der PCN führen.  
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Mit dieser Arbeit wurde gezeigt, dass die PCN von ColE1-Plasmiden über die 
Expression einer chromosomalen Kopie des RNAI-Gens unter dem pLlacO-1 Promotor 
reguliert bzw. reduziert werden kann. Die Expression des chromosomalen tRNAAla-
Gens bewirkte, entgegen den Erwartungen, eine Senkung der PCN.  
 6 
1 Introduction ....................................................................................................... 8 
1.1 Bacterial Plasmids ........................................................................................ 8 
1.1.1 ColE1 replication mechanisms .............................................................. 9 
1.2 DNA as a pharmaceutical product .............................................................. 11 
1.2.1 Therapeutic plasmids .......................................................................... 11 
1.2.2 pDNA for Gene Therapy and DNA vaccines ....................................... 12 
1.2.2.1 DNA vaccines .................................................................................. 13 
1.3 Genomic Engineering of pDNA production hosts ....................................... 15 
1.3.1 Homologous recombination in E.coli ................................................... 16 
1.3.2 Chromosomal integration of linear DNA fragments ............................. 17 
1.3.2.1 Insertion of linear DNA fragments by RecET recombinase .............. 17 
1.3.2.2 Insertion of linear DNA fragments by P1 Transduction .................... 17 
1.4 Inducible expression of genes .................................................................... 19 
1.4.1 The T7-System .................................................................................... 19 
1.4.2 Tight regulation of gene expression via highly controllable promoters 20 
2 Objectives ........................................................................................................ 22 
3 Material and Methods ...................................................................................... 23 
3.1 Media, growth conditions and storage of bacterial strains .......................... 23 
3.1.1 Media .................................................................................................. 23 
3.1.2 Shake flask cultures ............................................................................ 24 
3.1.3 Bacterial kryostocks ............................................................................ 25 
3.2 Bacterial strains and vectors ...................................................................... 25 
3.2.1 Bacterial strains ................................................................................... 25 
3.2.2 Plasmids.............................................................................................. 26 
3.3 Molecularbiological methods ...................................................................... 26 
3.3.1 Polymerase chain reaction (PCR) ....................................................... 26 
3.3.1.1 Colony PCR ..................................................................................... 27 
3.3.1.2 Cloning PCR .................................................................................... 27 
3.3.2 Assembly of oligonucleotides and fill-in, using DNA Polymerase I 
(Klenow) 30 
3.3.3 Agarose gel electrophoresis ................................................................ 30 
3.3.4 Purification of DNA .............................................................................. 31 
3.3.5 Restriction enzyme digestion .............................................................. 32 
3.3.6 Ligation ............................................................................................... 32 
3.3.7 Plalsmid preparation ........................................................................... 33 
3.3.8 Sequencing ......................................................................................... 34 
3.3.9 Electro transformation ......................................................................... 34 
3.4 Genomic engineering ................................................................................. 35 
3.4.1 Chromosomal integration of linear DNA by homologous recombination
 35 
3.4.1.1 P1 Transduction .............................................................................. 36 
3.4.1.2 Chromosomal integration of linear DNA fragments using the pRed/ET 
system 37 
3.5 Analytical methods ..................................................................................... 38 
3.5.1 Determination of Plasmid Copy Number ............................................. 38 
3.5.1.1 Calculation of PCN using Agilent 2100 Bioanalyzer (Agilent 
Technologies) ................................................................................................ 38 
3.5.1.2 Determination of dried biomass ....................................................... 41 
3.5.1.3 Determination of total amount of DNA by fluorimetric measurement 41 
3.5.1.4 Final calculation of PCN per cell ...................................................... 43 
3.5.2 Pour-plate method ............................................................................... 43 
 7 
4 Results and Discussion .................................................................................. 44 
4.1 Down regulation of plasmid copy number via inducible expression of RNAI
 44 
4.1.1 Regulation of plasmid copy number via inducible expression of RNAI 
under the control of the T7 promoter ................................................................. 45 
4.1.1.1 Construction of the T7-RNAI plasmid .............................................. 45 
4.1.1.2 Amplification of linear T7-RNAI fragment ........................................ 46 
4.1.1.3 Integration of T7-RNAI fragment into HMS174 (DE3) chromosome 46 
4.1.1.4 Bacterial cell growth under induced and uninduced conditions ....... 47 
4.1.1.5 Pour plate assays ............................................................................ 48 
4.1.1.6 Determination of pDNA concentration ............................................. 50 
4.1.2 Regulation of plasmid copy number via inducible expression of RNAI 
under control of the pLlacO-1 promoter ................................................................. 52 
4.1.2.1 Construction of the pBSK::TN7<CAT-pLlacO-1-RNAI> vector ............ 52 
4.1.2.2 Impact of IPTG induction on replication of pBSK::TN7<CAT-pLlacO-1-
RNAI> plasmid ............................................................................................... 54 
4.1.2.3 Integration of pLlacO-1-RNAI fragment into JM109 genome .............. 55 
4.1.2.4 Bacterial growth under induced and uninduced conditions .............. 56 
4.1.2.5 Determination of pDNA concentration by plasmid preparation assays
 57 
4.1.2.6 Determination of PCN by Agilent 2100 expert bioanalyzer .............. 58 
4.2 Up regulation of plasmid copy number via inducible expression of 
uncharged tRNAs .................................................................................................. 61 
4.2.1 Construction of MCS-vector ................................................................ 61 
4.2.2 Construction of T7-tRNA plasmid ........................................................ 62 
4.2.3 Construction of linear T7-tRNAmut fragment for homologous 
recombination into E. coli chromosome ............................................................. 63 
4.2.4 Integration of T7-tRNAmut fragment into HMS(174)DE3 genome ........ 64 
4.2.4.1 Shake flask experiments and determination of plasmid concentration
 64 
4.2.5 Integration of T7-tRNAmut fragment into genome of relA- strains ......... 66 
4.2.5.1 Shake flask experiments and determination of plasmid concentration
 66 
5 Conclusion and Outlook ................................................................................. 69 
6 References ....................................................................................................... 71 
7 Appendix .......................................................................................................... 74 
8 Abbreviations .................................................................................................. 76 
9 Index of tables ................................................................................................. 77 
10 Index of figures ................................................................................................ 78 
11 Curriculum Vitae .............................................................................................. 79 
Formatted: Font:
Formatted: Font:
 8 
 
1 Introduction 
 
1.1 Bacterial Plasmids 
The majority of bacteria have only one circular chromosome suspended in the 
cytoplasm without a surrounding nuclear membrane. The chromosome size in a 
typical bacterial cell can range from 0.6-6 megabase paires (Mbp) (1) and is 4.64 
Mbp in Escherichia coli (E. coli) (2). In addition, tiny separate minichromosomes or so 
called plasmids exist in the cytoplasm of bacteria. Plasmid size can vary from 1 to 
over 200 kilobase pairs (kbp) and the number of identical plasmids within a single cell 
can range anywhere from one to even thousands. Plasmids are not required for 
normal growth but might become essential under special environmental conditions. 
They carry a handful of genes that usually have a protective role in the cell. These 
genes provide selective/competitive advantage to the plasmid-containing host as 
they often carry genes involved in antibiotic resistance, degradation of substrates 
foreign to the species or tolerance to heavy metals. Plasmids can also be transferred 
from one bacterial cell to another by 3 different mechanisms namely conjugation, 
transformation and transduction. This enables cells to exchange their genetic 
material and new genes can be transferred between members in the “common gene 
pool” (3). Generally bacterial plasmids are inherited in a very stable manner, 
independently from the cell chromosome. In the case of high-copy-number plasmids, 
the copy number and cell division ensure a very low frequency of plasmid loss. Low 
copy number plasmids posses certain mechanisms which enable their maintenance 
during cell growth in non selective conditions (4). So called plasmid addiction 
systems reduce the number of plasmid free cells. Two genes are necessary for a 
functional killer system: one gene encodes a stable toxin which is always a protein 
and the second gene encodes for an antidote with short lifetime which can either be 
an antisense RNA or a protein. In the case of plasmid loss, the toxin would kill its 
host cell, as there is no antidote that can neutralize the stable toxin. Different 
postsegregational killer systems exist in bacteria and are reviewed in (5).  
One example for such a mechanism is the toxin colicin E1 which is produced by the 
ColE1 plasmid and kills plasmid free cells. Further, there are also some plasmids that 
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are able to produce conjugation inhibitors that prevent other plasmids to enter the 
same host. Each plasmid has an origin of replication (ori) to provide for duplication of 
the plasmid within the host cell (6). Basically, plasmids can replicate in an 
autonomous and self-controlled way but they also extensively use the replication 
machinery of the host (7). 
 
 
1.1.1 ColE1 replication mechanisms 
 
There are several different replicons existing in E.coli including F, R and ColE1. The 
most widely used plasmids in biotechnology are derivatives of the plasmid pBR322 
which carry a ColE1 origin of replication. The characteristics of these plasmids are a 
theta replication mechanism, the production of high plasmid copy numbers, a 
relatively low molecular weight and the requirement of only host-encoded proteins. 
ColE1 plasmids have been extensively studied and used as vectors for gene therapy 
and DNA vaccines (8, 9). 
 
Two different RNA molecules are responsible for replication of ColE1 plasmids. They 
are encoded in a region of about 600 base pairs. RNAII is a 555 nucleotide molecule 
which acts as a primer for DNA Polymerase I and thus, mediates plasmid replication. 
When RNAII binds to the plasmid, it is cleaved by the host-encoded enzyme RNase 
H. Due to this cleavage the 3’OH of RNAII is released and can be then elongated by 
DNA Polymerase I. The second important RNA molecule that regulates plasmid 
replication is the 110 nucleotide RNAI. This molecule is able to bind to RNAII thereby 
inhibiting the primer function of RNAII and thus negatively controls plasmid 
replication. Interaction of RNAI and RNAII requires a folded structure of both 
molecules. In a first step RNAI and RNAII form a transient so called “kissing complex” 
which is followed by RNA duplex formation. The initial interaction of RNAI and RNAII 
is stabilized by a small, 63 amino acids long, dimeric protein that is called Rom or 
Rop. Rom/Rop processes the complementary loops for the formation of the “kissing 
complex” (Fig.1.1.) (8, 9, 10).  
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Different mutations concerning the different members of ColE1-replication machinery 
have been used to convert pBR322-derived plasmids into high copy number 
plasmids. The pUC19 plasmids for example carry a point mutation in the RNAII 
sequence providing high copy numbers (11, 12). 
 
Interestingly also uncharged tRNAs are able to influence the ColE1-replication 
mechanism. In E.coli wild type cells, amino acid starvation results in the appearance 
of large amounts of the alarmones guanosine pentaphosphate (pppGpp) and 
guanosine tetraphosphate (ppGpp). Production of these molecules is promoted by 
the ribosome associated protein RelA. RelA itself is activated by the binding of 
uncharged tRNAs to the ribosomal A site. Production of the alarmones results in the 
cessation of transcription of stable RNAs (rRNAs and transfer RNAs). This effect is 
termed the stringent response. As expression of ribosomal protein genes is controlled 
by rRNA levels, the stringent response includes a large-scale downregulation of the 
translation apparatus (13). In relaxed mutant cells (relA), production of ppGpp is 
inhibited. As a result, uncharged tRNAs are accumulating inside the cytoplasm. It 
was shown that in the presence of large amounts of tRNA, three products of specific 
cleavage of RNAI could be observed. It is not yet sure, if cleavage of RNAI is 
Fig.1. 1: Regulation of plasmids with ColE1 replication origin. (a) RNAII acts as a primer for 
DNA Polymerase I after being processed by RNase H. (b) By the binding of RNAI and the 
stabilization of the “kissing complex by Rop/Rom, plasmid replication is inhibited. (c) 
Uncharged tRNAs can interact with RNAI resulting in free RNAII which in turn enhances 
plasmid replication (picture taken from Grabherr et al., 2002).  
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mediated by a direct or an indirect effect of tRNA. However, this tRNA-induced RNAI 
decay further leads to free RNAII which can prime replication efficiently thereby 
leading to an increase in plasmid copy number (14).  
 
Recent studies showed that the ColE1-replication mechanism can also be used for 
an antibiotic free plasmid selection system. Although the injection of pDNA containing 
an antibiotic resistance gene is currently tolerated by regulatory authorities because 
of no alternatives, there are some risks that cannot be excluded involving for example 
gene transfer to environmental organisms. In this antibiotic free plasmid selection 
system, RNAI is able to bind to the mRNA of a certain modified repressor (TetR). The 
repressor itself inhibits the expression of an essential gene (murA) that is located on 
the host’s chromosome and involved in bacterial cell wall synthesis. If the ColE1-like 
plasmid is present in the host, RNAI is expressed and can bind to the repressor 
mRNA. As the repressor is inhibited by RNAI, the essential gene can be expressed 
and cells owning the plasmid are thus able to grow (10). 
 
1.2 DNA as a pharmaceutical product 
Plasmids are currently evaluated for DNA vaccination or gene therapeutic 
applications, both for human and veterinary indications. Thus, there is a rapidly 
growing need for high quality plasmid DNA for drug applications (8). 
 
 
 
1.2.1 Therapeutic plasmids 
 
Therapeutic plasmids used for medical purpose must carry several important genetic 
components: a prokaryotic replication origin, a eukaryotic promoter, a certain target 
gene a selection marker and a polyadenylation signal sequence (poly-A) (Fig.1.2.). 
The prokaryotic replication origin is necessary for the amplification and propagation 
of the plasmid within the host. The eukaryotic promoter is responsible for the 
expression of the target gene which encodes a therapeutic protein or RNA molecule. 
Usually, the marker gene constitutes an antibiotic resistance gene which allows 
plasmid propagation and selection for plasmid carrying clones. The poly-A sequence 
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is necessary for successful termination of transcription and further provides stability 
as well as effective translation (8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.2 pDNA for Gene Therapy and DNA vaccines 
 
Plasmid DNA has become especially important in the field of gene therapy and DNA 
vaccination, and, more recently, plasmid-based gene silencing is gaining importance. 
Whereas gene therapy involves the introduction of a gene into cells to produce a 
therapeutic protein to treat genetic diseases, DNA vaccination involves the 
introduction of a gene into cells to produce antigen to prevent infectious diseases. 
The expression of dsRNA from plasmids is another technology of rising medical 
interest as it is much cheaper than the chemical synthesis of double strand RNA and 
further allows large scale application (8).  
When dsRNA of a certain gene is expressed in the cells, it gets degraded by different 
enzymes. These enzymes are then screening other mRNAs for the same sequence. 
Once found, the mRNA gets degraded and no protein can be produced. This mode of 
action leads to silencing of the targeted gene.  
The advantage of plasmid-based drugs compared with protein-based gene therapy 
and vaccination is that they allow for better processing, quality control, and large-
Fig.1. 2: Design of therapeutic plasmid consisting of genetic 
components necessary for medical purpose (picture taken from Dhama 
et al., 2008).  
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scale production (11). Today the delivery of DNA instead of whole proteins is gaining 
more and more in importance (8).  
 
1.2.2.1 DNA vaccines 
Today, plasmid DNA is also used for the development of so called DNA vaccines. 
These vaccines constitute an effective way for the in vivo expression of desired 
proteins to initiate immune response. DNA vaccines should work as follows: The 
plasmid DNA carries a gene encoding a viral, parasitic or bacterial antigene that can 
be expressed in mammalian cells. When the plasmid is injected into the host, the 
gene is transcribed and translated into the antigenic protein. This protein then causes 
a specific immune response and antibodies are produced against the expressed 
antigen. Further, the class I-restricted MHC antigen presentation pathway for 
cytotoxic T-cell induction can be activated. The advantages of DNA vaccines include 
the simplicity of manufacture, biological stability, cost effectiveness and safety, ease 
of transport in lyophilized form and the ability to act in presence of maternal immunity. 
Furthermore, it is possible to combine different genes simultaneously, giving rise to 
multivalent vaccines (15).  
 
Another advantage of using DNA isolated from bacteria is the presence of 
unmethylated CG sequences in prokaryotic cells. These sequences act as natural 
adjuvants, stimulating the innate immunity through toll-like receptor (TLR) 9. 
Expression of the encoded protein will be automatically at a site where resident 
antigen presenting cells (APCs) such as dendritic cells are activated through 
stimulated TLR9. Once activated APCs cause local inflammation, enhanced antigen 
processing and presentation, venue of immune cells from the blood as well as 
migration of APCs to the lymphoid organs. All these effects are achieved by the 
injection of naked pDNA without any additional adjuvants. The major disadvantage of 
pDNA vaccines is their capacity to persist in vivo and their putative ability to modify 
the genetic information of some host cells by integration into the chromosome (16).  
 
Plasmid DNA is also used for anti-cancer vaccination. In order to be distinguishable 
from normal tissue cells by the immune system, cancer cells should present target 
structures on their cell surface. The ideal target antigen would be exclusively 
expressed in tumor cells with no expression in normal adult tissues. More and more 
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tumor associated antigens are getting identified today. They are classified into four 
different groups: differentiation antigens, cancer/testis (CT) antigens, mutated 
antigens and ubiquitous antigens, which are overexpressed in cancer cells. The first 
anti-tumor vaccine which was recently authorized is a pDNA coding for the human 
melanoma antigen tyrosinase and is used for the vaccination against melanoma in 
dogs (16). 
 
In the field of veterinary medicine, the last few years have seen numerous trials of 
DNA vaccines against various animal diseases like foot and mouth disease (FMD) 
and herpes virus infection in cattle, Aujeszky’s disease and classical swine fever in 
swine, rabies and canine distemper in canines, and avian influenza, infectious 
bronchitis, infectious bursa disease and coccidiosis in bird (15). 
Concerning DNA vaccine development for humans, there is a promising progress in 
the field of the treatment of multiple sclerosis. Three companies, namely Orchestra 
Therapeutics, Opexa Therapeutic and Bayhill Therapeutics have designed DNA 
vaccines to treat multiple sclerosis, which are already in phase II development and 
could reach the market by 2012 (17, 18, 19). 
Large Scale Production 
For the production of large amounts of plasmid DNA, recombinant E.coli cells are 
used routinely. Alternatively, in vitro methods for DNA production are very expensive 
and would afford specialized equipment. Purification of DNA is one of the most 
challenging parts of production procedure as it has to be separated from the very 
similar host DNA. In the pDNA production process there are three main base unit 
operations: fermentation, cell lysis and downstream processing (20).  
 
Plasmid Vector optimization 
Vectors have to be optimized before used in fermentation processes as they must 
ensure acceptable fermentation production yield and quality as well as an acceptable 
purity after downstream processing. Quality and yield of DNA are strongly affected by 
the organization of elements, as well as the specific elements included. AT rich 
regions for example have a negative influence on the supercoiling of DNA. These 
regions are susceptible to endogenous single stranded nucleases as their binding to 
each other is not that strong. Enrichment of supercoiled DNA is desirable because it 
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is generally regarded as the physiologically active conformation and thus optimal for 
the transfection of eukaryotic cells. (20, 21, 22). 
Further it is important to inhibit the formation of replication intermediates. These 
linear fragments are observed when the origin is close to and parallel with the CMV 
promoter, as in this case, replication tends to terminate. The function of plasmids in 
eukaryotic cells can also be disturbed because of certain sequence orientations (46, 
23, 24, 25). It was shown for example, that the orientation of the kanamycin 
resistance gene dramatically affects expression from the adjacent CMV promoter, as 
well as overall plasmid yield (26). All the points mentioned above have to be kept in 
mind when designing an effective plasmid vector.  
In order to obtain high yield of plasmid DNA, high copy number plasmids are used for 
pDNA production. However, a too extensive plasmid replication can also lead to a 
metabolic overload of the host. Therefore it is important to be able to regulate PCN. 
Therapeutic plasmids typically contain a ColE1 or pBR322 derived replication origin 
carrying certain mutations to increase replication frequency. Such mutations include 
for example a rop deletion or a G to A point mutation (28). Further there are 
temperature sensitive origins (e.g. pUC, pMM1, pMM7) which allow a 30- to 40-fold 
increase in PCN when temperature is shifted from 30°C to 42°C (27, 28)  
 
 
1.3 Genomic Engineering of pDNA production hosts 
Genomic engineering comprises different techniques. However, they all involve DNA 
manipulation. Today it possible to isolate single genes from an organism, determine 
the gene sequence, to manipulate or alter the base sequence and thereby the 
function of the protein and to transfer the isolated gene from one organism to 
another. One field of genomic engineering is the integration of linear DNA fragments 
into the chromosome of a certain host via homologous recombination (6). The 
mechanism of homologous recombination in E.coli is described in the next chapter. 
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1.3.1 Homologous recombination in E.coli 
 
The mechanism of homologous recombination is more fully established in E.coli than 
in eukaryotic cells. However, it is likely, that both cell types have much in common in 
this respect. The event of genetic recombination naturally occurs in vivo between two 
separated chromosomes that share homologous sequences. This genetic mixing is 
very important as it constitutes the basic for genetic diversity. 
The first step of homologous recombination is the so called single strand invasion 
which is mainly catalyzed by the enzyme RecA. During single strand invasion a 
single strand of DNA invades the DNA duplex molecule at a site of complementary 
base sequences. Multiple copies of RecA bind to the single stranded DNA and the 
3'end of the single strand inserts into the DNA duplex. It hybridizes via 
complementary sequences and displaces the original strand creating a structure 
called D-loop. The affinity of RecA to the DNA single strand is ATP dependent. When 
ATP is bound to RecA, it mediates strand invasion by binding to the DNA. Hydrolysis 
of ATP leads to loss of affinity and RecA dissociates again from the DNA.  
In order to create the free 3'ends of the invading strand, one strand of each DNA 
duplex must be nicked by an endonuclease. Both strands then invade 
complementary DNA duplexes thereby resulting in the formation of the so called 
Holliday junctions. The cross-over junction randomly moves along the chromosomes 
just as long as there is homology. This movement is called branch migration.  
In a last step, the DNA duplex bound together must be separated. This is done by 
nicking of the non invading strands. But before this can be carried out, the Holliday 
junction is rearranged in three dimensions to uncross the strands, a process called 
isomerization. The subsequent nicking of the noninvading strands results in the 
exchange of chromosome arms and in genetic recombination (6, 29). 
As the mechanism of homologous recombination is based on the presence of 
complementary sequences, it constitutes an appropriate tool for the insertion of DNA 
fragments flanked by homologous regions. In this way, external genes can be 
inserted into the host’s chromosome or functional genes can be disrupted. 
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1.3.2 Chromosomal integration of linear DNA fragments  
 
1.3.2.1 Insertion of linear DNA fragments by RecET recombinase 
The problem of transforming bacteria with linear DNA fragments is that there are 
exonucleases present inside the cells that degrade linear DNA. It has been shown, 
however, that mutants lacking exonucleases V of the RecBCD recombiation complex 
are transformable with linear DNA (22). The single mutation of recD has led to mutant 
strains that were still able of recombination but lacked exonuclease activity. But, as 
already known for a long time, many bacteriophages own recombination systems, 
much more efficient than those of the recD mutant strains. One of these efficient 
recombination systems is the λ Red system of phage lambda. This system includes 
three genes: exo, ß and γ whose products are called, Exo Bet and Gam. Gam inhibits 
the RecBCD exonuclease V. In this way Bet and Exo can gain access to DNA ends 
to promote recombination. Plasmids have been produced encoding the λ Red system 
like for example the pKD20 or pKD46 vector where the recombination system is 
under the control of an arabinose-inducible promoter (30). For integration into the 
host genome, linear DNA fragments with 36- to 50-nt homology extensions are 
produced by PCR. These fragments can than be used to transform E.coli cells 
carrying a Red helper plasmid (pKD20, pKD46, pRED/ET). Expression of the genes 
of the λ Red system promotes integration of the linear DNA fragment in a site specific 
way according to the complementary flanking sequences (30).  
 
1.3.2.2 Insertion of linear DNA fragments by P1 Transduction 
Another, older, method of chromosomal integration constitutes the use of the phage 
P1. As the γ-red gene, which is necessary for homologous recombination, is toxic 
under some conditions, chromosomal integration is not applicable in recA- strains of 
E.coli. (31). Since all production hosts for recombinant plasmid or protein production 
are recA-, as this mutation secures genomic stability, chromosomal engineering is 
performed in the wild-type environment of MG1655 and then transferred into the 
strain of choice by P1 viral transduction. Phage transduction is used to move 
selectable genetic markers from one “donor” strain to another “recipient” strain. 
Phage P1 is commonly used as a transducing agent because it is a generalized 
transducer giving rise to “transducing particles”. During the replication and lysis of the 
phage in a culture of bacteria, a small percentage of the phage particles will contain a 
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genome segment that contains the gene of interest. P1 packages approximately 90 
kb of DNA, so it is possible to transduce genes that are linked to a selectable marker. 
Once a phage population has been generated from a donor strain, the phage is used 
to infect a recipient host. Most of the bacteria are lysed by phage that packaged P1 
genomes, but a fraction of the phage inject a genome segment derived from the 
donor host. Homologous recombination then allows the incoming genomic segment 
to replace the existing homologous segment. The infected recipient bacteria are 
plated on a medium that selects for the genome segment of the donor bacteria. 
All of this would not work if the infectivity of the phage could not be controlled. 
Otherwise, phage released from neighbouring cells would infect and lyse the bacteria 
that had been infected with transducing particles. Phage P1 requires calcium for 
infectivity. Therefore, P1 infectivity can be controlled by growing in the presence and 
absence of calcium.  
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Fig.1.3: The pET vector 
(picture from Alberghina 
et al., 2000) 
1.4 Inducible expression of genes 
 
1.4.1 The T7-System 
 
The T7-system is one of the most widely used systems for recombinant protein 
production. It permits controlled induction of gene expression via IPTG and as the 
T7-promoter is a very strong one, leads to high transcription levels and protein yield. 
This strategy was developed in 1986 by W.F. Studier and B.A. Moffatt, who created 
an expression system which was highly selective for bacteriophage T7 RNA 
polymerase. The initial system involved two different methods of maintaining T7 RNA 
polymerase in the host cell – in one method, a lambda bacteriophage was used to 
insert the gene which codes for T7 RNA polymerase, and 
in the other, the gene for the polymerase was inserted 
into the host chromosome. This expression system has 
become known as the pET system. The pET vector 
contains several important elements –a T7 promotor 
which is specific to only T7 RNA polymerase, a lac 
operator which can block transcription, a multiple cloning 
site, an f1 origin of replication, a resistance gene, a 
ColE1 origin of replication and occasionally, some plasmids 
also carry a lacI gene which codes for the lac repressor 
protein, (Fig.1.3.). 
The first step in this expression system is to clone the gene of interest (GOI) into the 
vector at the multiple cloning site. Transcription of the GOI is restricted to the 
presence of the T7 RNA polymerase. The host cell is genetically engineered to 
incorporate the gene for T7 RNA polymerase, the lac promoter and the lac operator 
in its genome. The inducible promoter of the polymerase gene can then be activated 
by IPTG. The T7 RNA polymerase is expressed and quickly begins to efficiently 
transcribe the GOI (32). 
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1.4.2 Tight regulation of gene expression via highly controllable 
promoters  
 
Promoters like those of phage T7 or phage lambda, as well as the promoter of the lac 
operon have so far been widely used for the control of gene expression. However, all 
of these promoters also have serious limitations. Whereas the T7 system is a very 
strong and leaky one, which induces gene expression even in the absence of the 
inducer, the promoter of phage lambda PL is induced by the inactivation of its 
repressor cI 857 via a temperature shift. This principle does not permit quantitative 
control on the one hand, and causes pleiotropic effects on the other hand. In the 
case of Plac, the activation of this promoter by CRP/cAMP also affects many other 
operons and thus profoundly changes the metabolic state of the cell. For the 
construction of a tightly controllable promoter, the promoter PL of phage lambda was 
altered. This promoter is a strong promoter in vivo and can be efficiently repressed by 
cI, the lambda repressor. In order to create a promoter that can be activated by IPTG, 
the cI binding site was replaced by the lacO1 sequence. This operator 1 encoding a 
sequence that comprises a 18bp of the lacO1 core sequence in the spacer region 
and a 22bp sequence upstream of the promoter. In the absence of IPTG the PLlacO-1 
promoter is tightly repressed by the lac repressor (33).  
The PLtetO-1 promoter constitutes another tightly controllable promoter system and is 
obtained by the integration of the tetO2 sequence in the same way as described 
above. This promoter is tightly repressed by the Tet repressor and can be activated 
by the supply with anhydrotetraclycline (33, 12).  
For the construction of the Plac/ara-1 promoter, the Plac promoter was altered in different 
steps. In vivo this promoter is depressed by IPTG and activated by CRP/cAMP and 
shows intermediate activity (62, 30). The Plac/ara-1 promoter contains the following 
alterations and mutations: a point mutation at position -8 (T to A), a lac operator 
sequence in the spacer region, a wild-type operator sequence upstream of the 
promoter and a deleted CRP/cAMP binding site substituted by a recognition site of 
AraC. Due to the listed modifications, this promoter is well controllable and can be 
activated by either IPTG or L(+) arabinose (33, 34).  
All of the described inducible promoter systems require, of course, host strains, that 
are expressing appropriate repressors. The E.coli strain DH5αZ1 for example carries 
the genes encoding the TetR, the LacR as well as the spectinomycin resistance 
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marker in its genome. The repressors are thereby under the control of a constitutive 
promoter (33).  
The development of tightly regulatable promoters allows the expression of single 
genes or RNA in well defined amounts. Furthermore, it is important, that these 
promoters are at the same time highly depressable by the constitutive expression of 
its corresponding repressor protein. The quantitative and temporal regulation of gene 
expression allows the study of the impact of single genes on cellular physiology (33).  
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2  Objectives 
 
High production rates cause substantial metabolic stress for the host cell. In 
particular, strong expression systems or heavy plasmid replication tend to exceed the 
metabolic capacity of the host. Therefore, in order to maintain viability of a productive 
population during the entire bioprocess, it is important to be able to control plasmid 
replication rates. Via the control of PCN, the metabolic load can be tuned, therefore 
overstraining of the cell factory is avoided and thus, the yield of protein and plasmid 
DNA is maximized (9). 
 
The aim of the current work was to develop strategies for regulating the copy number 
of plasmids with a ColE1 replication origin in E.coli. Two different approaches were 
investigated: 
 
• Inducible expression of RNAI, the negative regulator of PCN 
and 
• Inducible expression of uncharged tRNAAla, positively regulating the PCN 
 
In order to achieve the aims of the current studies, the different working steps, listed 
below, were followed: 
 
1) Design and cloning of expression cassettes for the inducible expression of 
RNA or tRNAAla, respectively. 
 
2) Chromosomal insertion of the cloned constructs. 
 
 
3) Investigation of plasmid copy number behaviour upon induction of the 
expression constructs using various assays. 
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3 Material and Methods 
 
3.1 Media, growth conditions and storage of bacterial strains 
 
3.1.1 Media 
Bacterial cells were routinely grown in LB-media at 37°C shaking (table 3.1.). If cells 
did carry a resistance gene LB-media containing the appropriate antibiotic was used 
(table 3.2.). Cells were plated on LB-agar-plates supplied with antibiotics, if 
necessary. All antibiotics and other additives are listed in table 3.2. After 
electroporation, cells were put into SOC-medium for maximizing the transformation 
efficiency of competent cells (table 3.3.). All media were sterilised by autoclaving for 
20 minutes at 121°C and 2 bar. 
 
Table 3. 1: LB-medium (Luria-Bertani medium) 
Tryptone 10 g/l 
Yeast extract  5 g/l 
NaCl 10 g/l 
 
The components for the LB-medium were dissolved in 950 ml sterile deionized water 
and pH was set to 7.0 with 5 N NaOH. Volume was adjusted to 1 liter. For LB-agar, 
15 g agar-agar was added per 1 liter LB-Medium. The autoclaved media was cooled 
to approximately 50°C before addition of an antibiotic stock solution.  
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Table 3. 2: Additives 
 STOCK 
SOLUTION 
FINAL  
CONCENTRATION 
ANTIBIOTICS   
ampicillin  100 mg/ml 100 µg/ml 
kanamycin 50 mg/ml 50 µg/ml 
chloramphenicol 25 mg/ml 25 µg/ml 
tetracycline 15 mg/ml 15 µg/ml 
OTHER ADDITIVES   
IPTG 0.1 M 100 µmol 
NaCitrate 1 M 10 mM 
CaCl2 1 M 5 mM 
glucose 20% 0.2% 
l-arabinose 20% 0.2% 
 
Table 3. 3: SOC-medium 
A bacto tryptone 20 g/l 
 yeast extract 5 g/l 
 NaCl 10 mM 
 KCl 3 mM 
 MgCl2 10 mM 
B glucose*H2O 20 mM 
C MgSO4*7H2O 10 mM 
A, B and C were autoclaved separately and mixed afterwards. 
 
3.1.2 Shake flask cultures 
Over night cultures were grown at 37°C shaking. The next day, cultures were diluted 
1:100 in LB-medium supplied with the corresponding antibiotic. Induction of gene 
expression was achieved by adding 100 µM IPTG at an OD600 of 0,3 or by adding 
IPTG directly to freshly inoculated cultures. Cells were grown on 37°C at 180 rpm 
after induction. Uninduced control flasks were always included in the experiments.  
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3.1.3 Bacterial kryostocks 
For conservation of bacterial strains, kryostocks were prepared. Therefore, an E.coli 
over night culture was grown in 3 ml of appropriate medium, at 37°C shaking. The 
next day, 600 µl of cell suspension and 300 µl of glycerine (80 %) were mixed in a 
1,5 ml Eppendorf tube, and frozen at -80°C.  
 
 
3.2 Bacterial strains and vectors 
 
3.2.1 Bacterial strains 
Bacterial strains listed in table 3.4. were used for the different experiments. 
 
Table 3. 4: Description of bacterial strains 
HOST  SOURCE GENOTYPE RESISTAN
CE 
HMS174 (DE3) Novagen F– recA1 hsdR(rK12– mK12+) 
(DE3) 
RifR 
DH5α Invitrogen F- 80dlacZM15 (lacZYA-argF) 
U169 recA1 endA1 hsdR17(rk-, 
mk+) phoA supE44 - thi-1 gyrA96 
relA1 
- 
JM109 Lab stock recA1 supE44 endA1 hsdR17 
gyrA96 relA1 thi ∆(lac-proAB) 
- 
MG1655 Lab stock F- lambda- ilvG- rfb-50 rph-1 - 
NEB10ß New England 
Biolabs (NEB) 
araD139 Δ(ara-leu)7697 fhuA 
lacX74 galK (Φ80 Δ(lacZ)M15) 
mcrA galU recA1 endA1 nupG 
rpsL Δ(mrr-hsdRMS-mcrBC) 
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3.2.2 Plasmids 
For the different experiments, plasmids listed in table 3.5. were used. 
 
Table 3. 5: Description of vectors used 
VECTOR  PROVIDED BY RESISTANCE 
pBluescript KSII+ Stratagene AmpR 
pkD46 Datsenko, 2000;  
kindly provided by Joseph E. Peters 
AmpR,  
temperature sensitive 
pTSA29recA Philips, 1998;  
kindly provided by Joseph E. Peters; 
AmpR, 
temperature sensitive 
pBR322 MBI Fermentas AmpR, TetR 
pBad Invitrogen AmpR 
pET11a Novagen AmpR 
pRED/ET Gene Bridges AmpR, TetR 
pUC19 MBI Fermentas AmpR 
pUC19∆RNAI Lab stock AmpR 
 
 
3.3 Molecularbiological methods 
 
3.3.1 Polymerase chain reaction (PCR) 
All PCRs were carried out in a Biometra T3-Thermocycler. Lyophilized primers, 
obtained from Sigma-Aldrich (St.Louis, MO, USA) were dissolved with sterile water, 
resulting in a stock solution with a concentration of 1 ng/µl. The primer working 
solution was obtained by a 1:100 dilution of the primer stock giving a final 
concentration of 10 pmol/µl. In the case of templates with a complex secondary 
structure, 1-5 % dimethyl-sulfoxide (DMSO) was added to the reaction mix. The 
melting temperature is dependent on the amount of Adenine (A), Thymine (T), 
Guanine (G) and Cytosine (C), and was calculated according to the following formula: 
 
Tm[°C] = 4 x (amount of G and C) + 2 x (amount of A and T) 
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3.3.1.1 Colony PCR 
For the screening of different colonies in consideration of the expected genotype, a 
colony PCR using a Taq polymerase, purchased from Biotools B&M Labs (Madrid, 
Spain), was used. The reaction mix was prepared as follows:  
 
3 µl 10x buffer 
1,2 µl MgCl2 (2mM) 
0,3 µl dNTPs (10mM) 
0,3 µl sense primer 
0,3 µl antisense primer 
0,15 µl polymerase 
24,75 µl H2O 
Σ 30 µl 
 
Colonies were picked with a sterile pipette tip, and were directly inoculated into a 
PCR tube containing the reaction mix. Tubes were placed into the Thermocycler and 
the following program was performed, as described below: 
 
initial denaturation 95°C 2min 
 94°C 30sec 
30 cycles lower primer Tm-3°C 30sec 
 72°C 1min/kb 
final extension 72°C 5min 
 
3.3.1.2 Cloning PCR 
As the Taq polymerase has no proofreading activity, it is not suitable for cloning 
purposes. In such cases, the Phusion DNA polymerase, purchased from Finnzymes 
(Espoo, Finnland) or the KOD DNA polymerase, purchased from Merck (Darmstadt, 
Germany), were used, respectively.  
 
The Phusion High-Fidelity DNA Polymerase combines a Pyrococcus-like enzyme 
with a processivity-enhancing domain. By fusing a double-strand DNA binding 
domain to the polymerase, its processivity can be increased. As a result of this 
combination, shorter extension times, more robust and high yield amplification, and 
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the ability to copy long templates in a fraction of time can be achieved. The reaction 
mix for a PCR using the Phusion polymerase was prepared as follows: 
 
10 µl Phusion HF Buffer 
1 µl dNTPs (10mM) 
2,5 µl  sense primer  
2,5 µl antisense primer 
x µl template 
0,5 µl polymerase 
up to 50 µl with nuclease free water 
Σ 50 µl 
 
The following program was use: 
initial denaturation 98°C 30sec 
 98°C 5-10 sec 
25-35 cycles 45-72°C (lower primer Tm+3°C) 10-30 sec 
 72°C 15-30 sec 
final extension 72°C 5-10 min 
 
For complex and long templates the KOD polymerase was used. This DNA 
polymerase is a recombinant form of Thermococcus kodakaraensis KOD1 DNA 
polymerase. It is a high fidelity thermostable polymerase, amplifying target DNA up to 
6 kbp. The KOD Polymerase produces blunt-ended DNA products. The standard 
reaction set up is described below: 
 
5 µl 10x buffer 
3 µl MgCl2 (25mM) 
5 µl dNTPs (2mM) 
2 µl sense primer 
2 µl antisense primer 
0,4 µl KOD DNA Polymerase 
x µl template DNA (0,006-6ng) 
up to 50 µl with nuclease free water 
Σ 50 µl 
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For DNA amplification using KOD polymerase, the following program was used: 
 
Cycling 
parameters 
0,5kbp target 
DNA 
1-2kbp target 
DNA 
3-4kbp target 
DNA 
5-6 kbp target 
DNA 
1. Denature 15s 98°C 15s 98°C 15s 98°C 30s 98°C 
2. Anneal 1-30 s 68°C 2s lowest primer 
Tm°C 
5s lowest primer 
Tm°C 
30s lowest primer 
Tm°C 
3. Extend none 20s 72°C 40s 72°C 60s 72°C 
4. Repeat steps 
1-3 
20-30 cycles 20-30 cycles 20-30 cycles 20-30 cycles 
 
If a polymerase with an exonuclease activity was necessary, the Deep Vent 
polymerase, purchased from New England Biolabs (NEB) (Ipswich, MA, USA) was 
used. This enzyme posses a 3`- 5` proofreading exonuclease and strand 
displacement ability. The term strand displacement describes the ability to displace 
downstream DNA, encountered during synthesis.  Deep Vent polymerase is therefore 
able to digest primers that bind more than once to a certain template (used during 
cloning of the RNAI expressing plasmids).  
 
Deep Vent polymerase is purified from a strain of E. coli that carries the Deep Vent 
DNA polymerase gene from a Pyrococcus species. The native organism was isolated 
from a submarine thermal vent at 2010 meters and is able to grow at temperatures as 
high as 104°C. This polymerase yields very long primer extensions with the longest 
product length to date of 14 kb thereby producing blunt-ended DNA fragments.  
In a standard PCR using the Deep Vent polymerase, the following 50 µl reaction was 
prepared in a 0,5 ml PCR tube on ice: 
 
5 µl TermoPol Reaction Buffer (10x) 
1 µl Deoxynucleotide Solution Mix (10mM) 
4 µl MgSO4 (100mM) 
2 µl sense primer 
2 µl antisense primer 
0,5 µl Deep Vent polymerase 
1 – 10 ng template DNA 
x µl nuclease free water 
∑ 50 µl 
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For amplification of DNA using the Deep Vent polymerase, the following program was 
used: 
Initial Denaturation 95°C 2-5 minutes 
 95°C 15-30 seconds 
20 – 30 cycles 55-65°C 15-30 seconds 
 72°C 1 minute / 1000 bp 
Final Extension 72°C 5 minutes 
Storage 4°C ∞ 
 
All primers and their sequences are listed in point 7. “Appendix”. 
 
3.3.2 Assembly of oligonucleotides and fill-in, using DNA Polymerase I 
(Klenow) 
Two oligonucleotides with short overlapping sequences were mixed in a PCR tube 
(500 pmol of each oligo) and put into the Biometra T3-Thermocycler. The oligo mix 
was heated to 99°C and slowly cooled down to 36°C (0,5°C / minute). By this 
controlled drop of temperature the overlapping ends of the oligos could properly bind 
to each other. In order to fill up the remaining single stranded ends of the 
oligonucleotides, the following Klenow reaction mix was prepared: 
 
x µl oligo mix 
1 µl dNTPs (25mM) 
1 µl NEB 3 buffer 
1 µl Polymerase I Klenow 
 
The reaction mix was incubated for 15 minutes at room temperature and was 
inactivated for 20 minutes at 75°C, afterwards.  
3.3.3 Agarose gel electrophoresis 
In order to separate DNA according to its size, gel electrophoresis was performed 
using a 1 % agarose gel. To obtain 360 ml of liquid agarose solution, 3,6 g agarose 
and 7,2 ml of 50x TAE were mixed and filled up to 360 ml with sterile water. To melt 
the agarose, the solution was heated in the microwave until the agarose was 
completely dissolved. After the solution had cooled down, 10 µl of ethidium bromide 
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were added. After mixing carefully, gels were poured. Before samples were loaded 
onto the agarose gel, 1x BX buffer was added. Analytical gels were run at 130 V and 
preparative gels at 90 V. As running buffer 1x TAE buffer was used. After the 
samples were separated on the gel, DNA was visualized under UV-light. In the case 
of a preparative gel, DNA-bands were cut out using a small scalpel.  
50x TAE stock solution 
Tris base 242 g/l 
glacial acid 57.1 ml/l 
0,5 M EDTA (pH 8.0) 100 ml/l 
 
6x BX-loading buffer 
bromophenol blue 0.25 % (w/v) 
xylene cyanol FF 0.25 % (w/v) 
glycerol in H2O 30 % (v/v) 
 
 
3.3.4 Purification of DNA 
DNA was purified either by using a preparative agarose gel or by direct purification of 
a PCR reaction or other enzymatic reactions using the Qiaquick PCR and Gel 
Purification kit (Qiagen, Hilden, Germany). The purification steps were carried out 
according to the protocols. For the purification of small DNA fragments, the QiaexII 
Gel extraction kit (Qiagen, Hilden, Germany) was used or ethanol precipitation was 
carried out. In the case of ethanol precipitation, 2-3 volumes of 100 % ethanol as well 
as 1/10 volume of 3 M sodium acetate (pH 5.2) were added to the sample. After 
mixing, the solution was frozen over night at -20°C. Alternatively, the precipitate can 
also be frozen at -80°C for 20 minutes to 1 hour. The solution was then centrifuged at 
top speed in a microcentrifuge at 4°C for 30 minutes. The supernatant was discarded 
later on and the pellet was dried at room temperature. After drying, the DNA was 
dissolved in a defined amount of sterile water.  After ligation, DNA was extracted by 
isopropanol precipitation. The same amount of isopropanol was added to the 
samples. Everything was mixed, and incubated for 15 minutes at room temperature. 
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= 0,024 
The precipitate was centrifuged for 15 minutes at top speed and the DNA pellet was 
washed by adding 70 % ethanol (1,5fold of the amount of the original sample). After 
centrifugation, the supernatant was discarded and the pellet was dried at room 
temperature. The DNA was resuspended in a defined amount of sterile water.  
 
3.3.5 Restriction enzyme digestion 
Different restriction enzymes from NEB were used for vector linearization and control 
digestions. Every enzyme is provided with a certain buffer for an optimal working 
efficiency (NEB 10x buffers 1-4). In few cases it is also necessary to add BSA (100x 
stock solution) to the reaction mix. The amount of enzyme should never exceed 1/10 
of the total reaction solution. According to their working temperatures, the restrictions 
were carried out at either 25°C or 37°C. The reaction mixes were incubated in an 
Eppendorf heating block for about 2 hours. Some enzymes had to be heat 
inactivated by placing them at 65°C for 20 minutes.  
 
3.3.6 Ligation 
All ligations were carried out using the T4-DNA Ligase, purchased form NEB. 
Reaction mixes were either incubated at room temperature for 2 hours or at 16°C 
over night. Standard ligation was performed with a 5:1 molar ratio of insert DNA to 
vector DNA in a 10 µl set-up. The insert-vector-ratio was calculated as follows: 
 
Example for the calculation of vector-insert ratio when 3µl of vector DNA are used: 
 
vector (3000 bp): 24 ng/µl  
insert (200 bp):   15 ng/µl 
 
(3 µl x 24 ng/µl) 72    
     3000 bp 
 
0,024 x 5 = 0,12 
 
0,12 x 200 bp = 24 ng/µl of insert DNA 
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24 ng/µl / 15 ng/µl = 1,6 µl of insert should be used for an optimal ligation efficiency 
 
If the insert was obtained by PCR, it had to be phosphorylated in order to ligate it to 
the vector backbone. For this phosphorylation step, the T4 Polynucleotide Kinase 
from NEB was used. A 30 µl standard phosphorylation mix contained the following 
ingredients: 1 µl PNK, 3 µl T7-ligase buffer and 26 µl insert solution. The reaction mix 
was incubated at 37°C for 30 minutes.  
In order to inhibit relegation after lineariziation, vectors were dephosphorylated before 
ligation. Therefore 1 µl of Antarctic Phosphatase (NEB), 2 µl of Antarctic 
Phosphatase buffer and 27 µl of vector solution were mixed in a 30 µl preparation, 
incubated at 37°C for half an hour and finally inactivated at 65°C for 5 minutes.  
 
3.3.7 Plalsmid preparation 
Plasmids were isolated from cells by using the Promega Miniprep kit. Plasmid 
preparation was carried according to the appropriate protocols. For all Minipreps, 
cells from 3ml of an over night culture were harvested by centrifugation and lysed as 
described in the protocols. Plasmid DNA was isolated via columns and eluted with 
either the provided elution buffer or nuclease free water. Plasmid DNA was eluted 
with 50-80µl buffer/water depending on the required plasmid concentration.  
For higher concentrations of plasmid DNA, the Promega Pure YieldTM Midiprep kit 
was used following the protocol. In the case of a Midiprep, cells were harvested from 
a 50ml over night culture and finally eluted in 600µl of elution buffer or nuclease free 
water.  
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3.3.8 Sequencing 
DNA sequencing was carried out by either AGOWA GmbH (Berlin, Germany) or 
Eurofins MWG GmbH (Ebersberg, Germany). Samples that were sequenced by 
AGOWA had to be diluted with sterile water to the concentrations listed above.  
 
Plasmids 10 µl 80 ng/µl 
PCR products   
150-500 bp 10 µl 10 ng/µl 
500-1000 bp 10 µl 20 ng/µl 
1000-2000 bp 10 µl 40 ng/µl 
custom primers 4 µl  5 pmol/µl 
 
Samples sequenced by Eurofins MWG were diluted to the following concentrations: 
 
Plasmids 15 µl 50-100 ng/µl 
PCR products   
< 300 bp 15 µl 2 ng/µl 
300-1000 bp 15 µl 5 ng/µl 
> 1000bp 15 µl 10 ng/µl 
custom primers 15 µl 2 pmol/µl 
 
3.3.9 Electro transformation 
For the transformation of plasmids, electrocompetent cells of the strains NEB10ß, 
DH5α or JM109 were used. Cells were grown over night in 20 ml LB-medium at 
37°C, shaking. The next day the over night culture was diluted 1:100 in 400 ml LB-
medium and incubated again at 37°C shaking until an OD600 of 0,6-0,8 was reached. 
The following steps were all carried out on ice and using a cooled centrifuge (4°C), 
respectively. All solutions were precooled to 4°C. Cells were harvested by 
centrifugation (Beckman Avanti J-20 XP centrifuge, JLA10.500 rotor, 4000 rpm, 8 
minutes, 4°C) and the supernatant was discarded. Cells were washed three times 
with 1 mM HEPES (500 ml, 250 ml, 100 ml). After the last washing step, the pellet 
was resuspended in 30 ml 10 % glycerine. The suspension was transferred into JA20 
cups and centrifuged again. The pellet was finally resuspended in 3 ml 10 % 
glycerine. Aliquots of 50 µl were pipetted into iced 1,5 ml Eppendorf tubes and shock 
frozen in liquid N2. Electrocompetent cells were stored at -80°C. 
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Electroporation was done by using Biorad gene pulser at 2.5 kV, 1000 Ω and 25 µF. 
For electroporation, self made cuvettes were used: Brand Ultravette cuvettes (12,5 x 
12,5 x 45 mm) were pasted up with conductive aluminium foil. After transformation 
cells were recovered at 37°C in 500 µl SOC-medium for 30 minutes before plating 
them on LB-Agar plates, containing the appropriate antibiotic.  
 
For the transformation of linear DNA-fragments, MG1655 cells containing the pkD46 
plasmid were used. Cells were prepared freshly for every electroporation. Therefore, 
an over night culture was diluted 1:100 in 50 ml LB-amp-medium containing 500 µl 
20 % arabinose. Cells were grown at room temperature until an OD600 of 0,4-0,6 was 
reached. The pellet was washed four times with 1ml of ice cold water (Eppendorf 
microcentrifuge, 5000 rpm, 5 minutes, 4°C) and was finally resuspended in 150 µl of 
ice cold water. After electroporation, cells were incubated in 900 µl SOC-medium at 
37°C for 3-4 hours.  
 
 
3.4 Genomic engineering 
 
3.4.1 Chromosomal integration of linear DNA by homologous 
recombination 
Linear DNA fragments were obtained by PCR or by cutting them out of the 
corresponding vector. Fragments were loaded onto a preperative agarose gel, cut out 
and extracted according to section 3.3.4. E. coli MG1655 carrying the Red helper 
plasmid pKD46 (Datsenko, 2000) were grown in LB-amp medium over night. The 
next day, cells were diluted 1:100 in 50ml LB-amp containing 1% arabinose (20%). 
Cells were grown at room temperature, shaking until OD600 of 0,4-0,6 and made 
competent (see section 3.3.9.). Electroporation was done by using Biorad gene 
pulser at 2.5 kV, 1000 Ω and 25 µF. 100-300 ng of the gel purified linear cassette 
were used for transformation. After a recovery time of several hours in 900µl SOC 
medium, cells were plated onto appropriate agar plates and incubated over night at 
37°C.  
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3.4.1.1 P1 Transduction 
P1 phage lysat preparation 
MG1655 cells, with the linear DNA fragment integrated into their genome, were 
grown over night in LB-cm medium supplied with 5mM CaCl2. The over night culture 
was diluted 1:100 in 5 ml LB-cm medium containing again 5 mM CaCl2. 20 µl of a 
high titer P1 phage lysate were added to the donor cells. At the same time, controls 
only consisting of MG1655 cells without the phage lysat, were also put at 37°C 
shaking. The cultures were checked for lysis hourly (1h-6h). After cells were lysed, 
several drops of chloroform were added and the lysate was vortexed (chloroform kills 
phage-resistant bacteria and removes cell wall debris). The debris was removed by 
centrifugation (3500 g, 15 minutes, Jouan C312) and the supernatant was transferred 
to a new tube. In order to get rid of any remaining cells, the lysate was further 
pressed through a filter (22µm) and transferred to a light-safer container. The lysate 
was stored at 4°C. 
 
Transduction 
E.coli HMS174(DE3) carrying the pTSA29 (carries all genes necessary for 
homologous recombination) plasmid were grown over night in LB-amp medium 
supplied with 5mM CaCl at 30°C shaking. The next day, 300 µl of HMS174(DE3) 
cells were mixed with 100 µl of P1-lysate in 15ml tubes. The following working steps 
also include cells only and phage only controls. The cell-lysate, as well as the 
controls were incubated static at 37°C for 25 minutes. Then 5 ml of LB-medium 
supplied with 10 mM NaCitrat were added. The solutions were mixed and cells were 
pelleted (3500 g, 15 minutes, Jouan C312). The supernatant was discarded and the 
cell pellets were resuspended in 1 ml LB-NaCitrat solution. Cells were transferred 
into 1,5 ml Eppendorf tubes and incubated for at least 1 hour at 37°C shaking. 
Finally, cells were spread on selective agar plates (LB-cm) and incubated at 37°C. 
Colonies were cured from pTSA29 plasmid.  
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3.4.1.2 Chromosomal integration of linear DNA fragments using the pRed/ET 
system 
Alternatively, chromosomal integration of linear DNA 
fragments was achieved by using the Quick & Easy E. 
coli gene deletion kit, purchased from Genebriges 
GmbH (Heidelberg, Germany).  
With this kit, direct integration of a linear DNA fragment 
is possible and no P1 transduction has to be carried 
out. Plasmid pRed/ET (figure 3.1.), which basically can 
be introduced in any E.coli strain, represents the core 
of the Red/ET technology. In contrast to the pKD46 
plasmid, pRed/ET can be introduced also in recA-
negative strains because the plasmid additionally carries the recA gene. pRed/ET 
encodes for the phage λ recombination machinery. Redγ stabilizes the linear 
recombination partner so that exonuclease Redα and the DNA-binding protein Redß 
can mediate recombination between target molecules. Expression of the 
corresponding genes is under control of an inducible arabinose promoter. The 
addition of the inducer, followed by a temperature rise (30°C to 37°C) results in a 
transient recombineering activity, since pRed/ET is no longer replicated due to its 
thermosensitivie ori pSC101 and finally gets lost.  
Following the protocol, the pRed/Et plasmid was transformed into competent E.coli 
JM109 cells. An over night culture was inoculated in LB-amp medium. Half of the 
standard ampicillin concentration was used (50 µg/ml), due to the low copy nature of 
the pSC101 ori. The next day the over night culture was diluted 1:50 in 10 ml LB-amp 
medium and grown to an OD600 of 0,3 at 30°C shaking. The dilution was prepared 
two times, one of them representing the uninduced control. When cells had grown to 
the proper OD600, one of the cultures was induced by adding 0,3 % - 0,4 % arabinose 
(10 %). Both cultures were further incubated for one hour at 37°C shaking to allow 
expression of the pRed/ET genes. 2,5 ml of culture were harvested afterwards 
(Eppendorf microcentrifuge, 4 minutes, 5000 rcf) and washed 4 times with 1 ml of ice 
cold sterile water. After the last washing step, the supernatant was decanted, and the 
cell pellet was resuspended in the remaining water. 300-400 ng of linear fragment 
was mixed with ~40 µl of competent cells. Electroporation was done by using Biorad 
gene pulser at 2.5 kV, 1000 Ω and 25 µF. After electroporation, cells were transferred 
Fig.3 1: The pRed/ET plasmid 
for direct integration of linear 
DNA fragments (picture from 
Genebridges GmbH). 
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to 500 µl SOC-medium and placed at 37°C shaking for 3 hours. Finally cells were 
spread on a selective agar plate and grown over night at 37°C.  
 
 
3.5 Analytical methods 
 
3.5.1 Determination of Plasmid Copy Number 
 
3.5.1.1 Calculation of PCN using Agilent 2100 Bioanalyzer (Agilent 
Technologies) 
For the quantitative analysis of DNA, a chip has to be loaded which can then be 
inserted into the bioanalyzer for quantification of DNA.  The chip accommodates 
sample wells, gel wells and a well for an external standard (DNA ladder). Micro-
channels create interconnected networks among these wells. During chip 
preparation, the micro-channels are filled with a sieving polymer and fluorescence 
dye. Then, twelve samples and standard are loaded in each well. 
 
Once the wells and channels are filled, the chip becomes an integrated electrical 
circuit. The 16-pin electrodes of the cartridge are arranged so that they fit into the 
wells of the chip. Each electrode is connected to an independent power supply that 
provides individual control and flexibility.  
Charged biomolecules like DNA or RNA are electrophoretically driven by a voltage 
gradient, similar to slab gel electrophoresis. The molecules are separated by size. 
Dye molecules intercalate into DNA/RNA strands and these complexes are detected 
by laser-induced fluorescence. Data is translated into electropherograms (peaks).  
 
During the chip run, the dye intercalates directly with the DNA/RNA and all bands 
pass the detector at different time points. An extra “lower” marker fragment is run with 
each of the samples to compensate for drift effects that may occur during the course 
of a chip run. 
The software automatically compares the unknown samples to the ladder fragments 
to determine the concentration of the unknown samples and to identify the ribosomal 
DNA/RNA peaks. 
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Preparation of DNA samples 
All solutions used for plasmid DNA preperation were taken from Promega Miniprep 
Kit. Centrifugation steps were carried out by using an Eppendorf microcentrifuge. 
An over night culture of the cells under investigation was inoculated in LB-media and 
grown at 37°C shaking. The next day OD600 was measured, and a normalized 
number of cells (3 / OD600 = xml) was harvested. Cell pellets were resuspended 
thoroughly in 250µl of resuspension solution. 250µl of lysis buffer were added and 
tubes were inverted 4 times. At this point, 1µg of the internal standard (in our case 
pMCP-1 (4892 bp)) was added to the samples to compensate for losses during 
purification. In a next step, 10µl of alkaline protease solution was added, the samples 
were inverted again 4 times, and incubated at room temperature for 5 minutes. 
Afterwards 350µl of neutralization solution was added. After inverting the samples for 
another 4 times, they were centrifuged at top speed for 10 minutes. The supernatants 
were transferred to miniprep columns and centrifuged for 1 minute at top speed. The 
DNA was washed 2 times with wash buffer (750 µl, 250 µl) and columns were dried 
by centrifugation for 2 minutes at top speed. Finally plasmid DNA was eluted with 
50µl nuclease free water by centrifugation for 1 minute at top speed. 
 
Plasmid linearization 
For later quantitative analysis of DNA, both plasmids, from the internal standard as 
well as from the samples, had to be linearized. Therefore, an enzyme was chosen, 
with only one restriction site in both vectors. A master mix containing the enzyme, the 
buffer and if necessary sterile water was prepared. 25 µl of sample solution were 
mixed with 5 µl of the master mix and the restriction was incubated at the appropriate 
temperature for at least 1,5 hours. Finally, the restriction enzyme was inactivated by 
placing the reaction solution at 65°C for at least 30 minutes. Samples were stored at 
-20°C. 
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Loading the Biochip 
For proper handling of the bioanalyzer and all corresponding chemicals, the different 
points, described in the break “Essential Measurement Practice” of the Agilent 
protocol, were followed.  
 
Preparing the gel-dye mix 
Before starting, the DNA dye concentrate, as well as the DNA gel matrix, were 
equilibrated to room temperature for 30 minutes. The dye concentrate was vortexed 
for 10 seconds and spinned down. 25 µl of the dye concentrate were pipetted into a 
DNA gel matrix vial. The dye concentrate was stored again at 4°C in the dark. The 
tube containing gel and dye was vortexed for another 10 seconds and the mix was 
transferred to the top receptacle of a spin filter. The spin filter was placed in an 
Eppendorf microcentrifuge and spinned for 10 minutes at room temperature at 
4000rpm. Afterwards, the filter was discarded.  
 
Loading the gel-dye mi 
Before the mix was loaded to the biochip, it was equilibrated, if necessary, to room 
temperature for 30 minutes. During this time, the mix had to be protected from light. A 
new DNA chip was taken out of its sealed bag and placed on the chip priming station. 
9 µl of the gel-dye mix were pipetted at the bottom of the well marked G and the mix 
was dispensed. The plunger of the syringe of the chip priming station was pressed 
down until it was held by the clip. After 30 seconds the plunger was released. When 
the plunger had moved back to the 0,3 ml mark, it was slowly pulled back to the 1ml 
position after 5 seconds and the chip priming station was opened. Further, 9 µl were 
pipettet in two other wells marked.  
 
Loading the marker 
5 µl of the DNA marker were pipetted into the well marked with the ladder symbol 
and into each of the 12 sample wells.  
 
Loading the ladder and the samples 
1 µl of the DNA ladder were pipetted in the well marked with the ladder symbol. In 
each of the 12 sample wells, 1 µl of sample or 1 µl of deionized water was pipetted. 
The loaded chip was placed horizontally in the adapter of the IKA vortex mixer and 
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vortexed for 60 seconds at 2400 rpm. The chip was put into the Agilenta 2100 
bioanalyzer and the run was started within 5 minutes.  
 
 
3.5.1.2 Determination of dried biomass 
An appropriate amount of beakers was marked, and placed at 100°C over night. The 
next day, the beakers were transferred to the essicator and dried for 2-3 hours. 
Within the first half hour, the valve of the essicator remained open to allow the hot air 
to escape. The dried breakers were weighted using an analytical balance, and the 
measurements were noted.. 
An over night culture of E.coli cells under investigation was inoculated in 20ml LB-
media and grown at 37°C shaking. The next day, exactly 10 ml of each cell 
suspension were transferred to a 15ml plastic tube and centrifuged for 15 minutes at 
5000 rcf at 4°C (Eppendorf centrifuge 5804R). The cell pellets were washed 3 times 
with 1ml of ice cold water (5 minutes, 5000 rcf, 4°C, Eppendorf centrifuge 5804R). 
The pellets were resuspended in water and poured quantitatively into the according 
dried beakers. The beakers were again placed at 100°C over night and dried in the 
essicator the next day. The beakers containing the dried biomass were again 
weighed. The biomass was calculated and values were used for the determination of 
PCN per cell.  
 
3.5.1.3 Determination of total amount of DNA by fluorimetric measurement 
If not otherwise stated, all chemicals were purchased from Merck. 
 
10x TNE-buffer Tris 1M 
 EDTA 10mM 
 NaCl 1M 
 pH 7,4 with HCl 
 
Dilution buffer: 1:10 dilution of 10x TNE buffer (prepared freshly) 
 
Hoechst reagent: 100 ml dilution buffer + 10 µl Hoechst dye 33258 (10 mg/ml) 
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This reagent has to be prepared freshly when needed. It must be cooled and has to 
be protected from light. 
 
Solution I glucose 50 mM 
 EDTA 10 mM 
 Tris/HCl (pH 8,0) 25 mM 
 
 
SDS solution (Biorad): 0,5 % 
 
DNA-standard solution (Sigma): 1 mg of calve thymus DNA is dissolved in 1 ml of 
sterile water 
 
Lysozyme solution (Sigma): 10 mg/ml of lysozyme is dissolved in sterile water 
 
Determination of the total amount of DNA is achieved by fluorimetric measurement, 
using bisbenzimidazol (Hoechst-dye 33258). Bisbenzimidazol binds to DNA and 
therefore its fluorescence can be measured at 458 nm, with an excitation wavelength 
of 365 nm.  
Samples were prepared as follows:  
The OD600 of an over night culture was measured and a normalized number of cells 
was harvested (3 / OD600 = xml). 150 µl of solution 1 were added and the cell pellet 
was resuspended thoroughly. 50 µl of lysozyme solution were added and the sample 
was mixed again. After an incubation time of 10 minutes at 37°C 200 µl of SDS 
solution (0,5 %) were added, mixed and incubated for another 10 minutes at 37°C. 
8,6 ml dilution buffer were exhibited in 15 ml tubes and the viscous DNA solution was 
added. With 1 ml of dilution buffer the remaining DNA solution was washed out and 
transferred into the tube. The tubes were vortexed thoroughly and kept on ice until 
measurement.  
For calibration, different dilutions of calve thymus DNA in a concentration range of 0-
6 µg/ml were used. 
15 µl of sample and standard solution were pipetted into a 96 well plate and 280 µl of 
the Hoechst reagent were added using a multichannel pipette. Measurements were 
carried out using a Molecular Devices fluourimeter from Spectramax Gemini. 
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Calculation of DNA concentration was performed automatically based on the 
calibration curve obtained by the calve thymus DNA standard solution.  
 
 
3.5.1.4 Final calculation of PCN per cell 
The calculation of the PCN did require the results of the bioanalyzer assay, the 
amount of dried biomass as well as the results from the fluorimetric measurements of 
the total DNA. All data was combined and the PCN per cell was calculated using the 
following formula: 
 
size of chromosome [bp] x pDNA [µg] 
average size of plasmid [bp]  
 
3.5.2 Pour-plate method 
In order to check, whether plasmids were segregationally stable, the pour-plate 
method according to Koch was applied. Therefore, E.coli cells were grown over night 
in LB-medium without any antibiotics at 37°C shaking. The next day, cell cultures 
were diluted to a normalized OD600 value again in LB-medium. After 3 hours of 
growth at 37°C, gene expression was induced by adding 100 µM IPTG. After another 
3 hours, cells were diluted in SOC-media to an appropriate amount of cells per 
millilitre. Three dilutions were plated on LB-plates and LB-selective-plates, 
respectively. The plates were incubated over night at 37°C. The next day, growing 
colonies were counted and a mean value from the three dilutions was calculated.  
x chromosomal DNA [µg] 
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4 Results and Discussion 
 
4.1 Down regulation of plasmid copy number via inducible 
expression of RNAI 
 
The replication of ColE1-type origin is regulated by the two RNA molecules RNAI and 
RNAII. Both molecules are encoded on the plasmid itself. The 555-nucleotide RNAII 
can bind at the origin of replication thereby acting as a primer for DNA polymerase I. 
This is only possible when RNAII is not bound by RNAI. The RNAI molecule is a 
short 110-nucleotide antisense molecule and acts as an inhibitor of RNAII (35).  
 
In the following experiments, regulation of plasmid copy number was tried to be 
achieved by a chromosomal copy of RNAI under the control of an inducible promoter. 
Therefore two different linear fragments were designed. The first consisted of the T7 
promoter, followed by the RNAI sequence. The second fragment was composed of 
the RNAI sequence under the control of the pLlacO-1 promoter. In both cases 
chloramphenicol resistance was used as selection marker.   
The RNAI-fragments were integrated into the chromosome of HMS174(DE3) via 
homologous recombination. In order to investigate the impact of RNAI 
overexpression, HMS174(DE3) cells were transformed with different plasmids. 
Replication of the pUC19 plasmid, a RNAI-deleted version of the pUC19, designated 
pUC19∆RNAI and, in some cases, the low copy number plasmid pBR322 were 
investigated. In the case of the pUC19∆RNAI plasmid, the -10 and the -35 box of the 
RNAI promoter were deleted and thus, no RNAI was expressed from this plasmid. 
Shake flask experiments, wherein cells were grown in medium with and without 
IPTG, were carried out, and the plasmid copy numbers were determined  
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4.1.1 Regulation of plasmid copy number via inducible expression of 
RNAI under the control of the T7 promoter 
 
4.1.1.1 Construction of the T7-RNAI plasmid 
 
For the construction of a plasmid carrying the RNAI sequence under the control of 
the T7 promoter, the pBSK::TN7<CAT-T7-GFP>shown in figure 4.1., was used as a 
template vector. The pBSK::TN7<CAT-T7-GFP> vector did carry the reporter gene 
GFP which was already under the control of the T7 promoter and terminated by the 
T7 terminator. Primers with overlapping ends binding to the T7 promoter on the one 
hand and to the T7 terminator of the GFP gene on the other hand were designed. 
The overlapping ends were thereby representing the sequence of RNAI. Two PCRs 
were carried out using the pBSK::TN7<CAT-T7-GFP> as template and the primer 
pair T7prom-RNAI overlap and m13-20back as well as the primer pair T7term-RNAI 
and ColEIfor. For these PCRs, the Deep Vent polymerase was used because of its 
strand displacment activity. As primers could also bind to the ori, this strand 
displacement property enables the polymerase to digest the binding primers and to 
proceed with the PCR. The two fragments with a length of 1350 bp and 1554 bp 
respectively were loaded onto a preparative agarose gel. The fragments were cut out 
and DNA was extracted by using the Qiagen Qiaquick PCR Purification and Gel 
Purification kit. One of the two fragments was phosphorylated with T4 Polynucleotide 
Kinase as described in section 3.3.6. The fragments were ligated at room 
temperature and precipitated with isopropanol. The emerging plasmid is shown in fig. 
4.1.  
 
 
 
 
 
 
 
 
 
 
Fig.4 1: Original pBSK vector a) and vector carrying the RNAI gene under the 
control of the T7 promoter b). This vector was created by the use of primers 
with overlapping ends constituting the RNAI. 
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The pBSK::TN7<CAT-T7-RNAI> was transformed into competent NEB10ß cells. 
Growing colonies were checked by PCR screening, using the primers m13-20 back 
and T3. Plasmids of positive colonies were isolated by a Miniprep kit and cut with the 
restriction enzyme HindIII. As the control restriction showed the expected bands on 
an agarose gel, plasmids were sequenced.  
 
4.1.1.2 Amplification of linear T7-RNAI fragment 
In order to obtain a linear T7-RNAI fragment the pBSK::TN7<CAT-T7-RNAI> vector 
was used as template. For the amplification of the fragment, a PCR was carried out, 
using KOD or Phusion DNA polymerase, respectively together with primers m13-20 
back and T3. A linear T7-RNAI fragment as shown in fig. 4.2. was obtained. The PCR 
product was loaded onto an agarose gel, cut and purified according to the 
manufactures instructions. To get rid of any remaining vector template, the extracted 
DNA was digested using the enzyme DpnI that only cuts methylated DNA. After 
digestion, the T7-RNAI fragment was purified again using a PCR-purification Kit.  
 
 
 
 
 
 
4.1.1.3 Integration of T7-RNAI fragment into HMS174 (DE3) chromosome 
For chromosomal integration, MG1655 cells were transformed with the linear T7-
RNAI fragment by electorporation. Growing colonies were screened using a primer 
pair, that bound on the one hand to the cm-resistance gene of the linear fragment 
(cat begin for) and on the other hand in the MG1655 genome (TN7/2-HO-for), 
resulting in a 781 bp band. To make sure, that the growing colonies did not gain their 
antibiotic resistance from a remaining undigested pBlueScript vector, another PCR 
screening was carried out, using plasmid ori- primers (RNAII 115 back, RNAII 625 
for) resulting in a 497 bp fragment.  
 
The T7-RNAI fragment was transferred to the recipient strain HMS174(DE3) by P1 
transduction. 
Fig.4 2.: Linear T7-RNAI fragment obtained by PCR. The fragment carries a chloramphenicol 
resistance gene as selection marker and is flanked by homologous sequences (dark blue bars) for the 
later intergration into the HMS174(DE3) genome. 
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A successful homologous recombination of the T7-RNAI fragment was checked by 
PCR using the primers cat begin for and TN7/2 extern. A fragment of 831 bp was 
obtained indicating that the recombination event had taken place at the right genome 
locus. As this screening PCR was carried out with the Phusion polymerase, the 
amplified fragments could be directly sequenced.  
Competent HMS174(DE3) cells were transformed with the pUC19 plasmid as well as 
with the pUC19∆RNAI plasmid. As controls, HMS174(DE3), that did not carry the 
RNAI genome modification, were transformed with these plasmids. 
 
4.1.1.4 Bacterial cell growth under induced and uninduced conditions 
In order to check whether IPTG influences cell growth, over night cultures of the 
strains HMS174(DE3)::TN7<CAT-T7-RNAI>, HMS174(DE3)::TN7<CAT-T7-
RNAI>pUC19 and HMS174(DE3)::TN7<CAT-T7-RNAI>pUC19ΔRNAI were 
inoculated in 10 ml LB-medium, supplied with the appropriate antibiotics (cm, 
cm/amp). The next day, cell cultures were diluted to the same OD600 in another 10 ml 
medium and different concentrations of IPTG were added. Cell growth was observed 
by measuring the OD600 after one, two and three hours. Measured growth values are 
listed in table 4.1. 
 
Table 4. 1: Bacterial cell growth of different HMS strains with and without IPTG 
 HMS174(DE3)::TN7<
CAT-T7-RNAI> 
 
   1h         2h        3h 
HMS174(DE3):: 
TN7<CAT-T7-
RNAI>pUC19 
   1h         2h        3h 
HMS174(DE3):: 
TN7<CAT-T7-
RNAI>pUC19∆RNAI 
  1h         2h        3h 
no IPTG  0,087   0,432   1,333 0,098   0,292   0,843 0,083   0,345   0,969 
100 µM 
IPTG 
0,078   0,319   0,603 0,078   0,199   0,348 0,077   0,259   0,364 
25 µM 
IPTG 
0,073   0,395   1,199 0,1       0,327   0,815 0,098   0,346   0,881 
2,5 µM 
IPTG 
0,074   0,355   1,193 0,86     0,273    0,824 0,093   0,369   0,932 
 
Low concentrations of IPTG (2,5 µM, 25 µM) did not influence cell growth of any of 
the three strains, significantly. The addition of 100 µM of IPTG however led to a lower 
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growth rate, as the OD600 measured herein, reached only half the value of IPTG-free 
cell cultures. At this point it can be stated that IPTG, when added in concentrations of 
100 µM, had a toxic effect on the cells as it reduced cell growth in the case of all 
three E.coli strains. Andersson et al. already showed, that induction with 0,1 µM 
IPTG results in a decrease of cell growth as well as of cell mass (36). Previous 
publications could demonstrate, that the addition of IPTG to wild-type E.coli leads to 
elevated expression of several stress response proteins and therefore to a reduced 
cellular growth rate (37). Andersson et al. further showed that the presence of 
plasmids also effects cell growth and causes a decline in the colony forming ability of 
cells (36). As those cells that were carrying plasmids are showing a reduced OD600 
value even in the absence of IPTG, this might also be the case in this experiment. 
Addition of IPTG should induce RNAI overexpression, and thus lead to an inhibition 
of plasmid replication. If plasmid replication is inhibited plasmid loss and therefore 
growth stagnation could be expected under selection pressure as this was the case 
for the induced cell cultures.  
 
4.1.1.5 Pour plate assays 
In the next experiment, over night cultures of the strains listed in table 4.2. were 
grown in 10 ml LB-medium. The next day, cell suspensions were diluted to a 
normalized OD600 value in fresh LB-medium (10 ml). After 2 hours of growth, IPTG 
(100 µM) was added to the cells and OD600 was measured hourly (table 4.2.). After 3 
hours, two different dilutions from each cell culture were spread on LB- as well as on 
LB-amp agar plates and incubated over night at 37°C. The next day, colony forming 
units (cfu) were determined (table 4.3.).  
 
 
 
 
 
 
 
 
 
Formatted: Font: Arial
Formatted: Font: Arial
Formatted: Font: Arial
 49 
Table 4. 2: Bacterial cell growth in LB-medium after addition of IPTG 
 OD600 
when IPTG was 
added (100 µM) 
OD600 
after 1 hour  
OD600 
after 2 hours  
OD600 after 
3 hours  
HMS174(DE3)+pUC19 0,107 0,151 0,524 1,020 
HMS174(DE3)::TN7<CAT-
T7-RNAI>  
0,387 0,998 1,912 2,460 
HMS174(DE3)::TN7<CAT-
T7-RNAI>pUC19 
0,578 1,364 2,416 3,025 
HMS174(DE3)::TN7<CAT-
T7-RNAI>pUC19∆RNAI 
0,519 1,109 1,874 2,515 
HMS174(DE3)+ΔRNAI 0,508 1,030 2,116 3,250 
 
 
Table 4. 3: Cfu’s on LB- and LB-amp plates after 3 hours of growth in liquid LB-medium supplied with 
100µM IPTG 
  D1                     D2   
  LB Amp LB Amp 
 HMS174(DE3)+pUC19 600 468 57 39 
HMS174(DE3)::TN7<CAT-T7-RNAI>  463   2   
HMS174(DE3)::TN7<CAT-T7-RNAI>pUC19 522 0 61 0 
HMS174(DE3)+pUC19ΔRNAI 350 9 59 1 
HMS174(DE3)::TN7<CAT-T7-
RNAI>pUC19∆RNAI 
230 0 44 0 
 
The results of the pour plate assay showed, that the pUC19 plasmid could be stably 
propagated. As the number of growing colonies on LB-amp agar plates was not 
significantly lower than the number of colonies that grew on LB agar plates, it was 
shown, that the majority of cells did still carry the pUC19 plasmid. In the case of the 
HMS174(DES)::TN7<CAT-T7-RNAI>pUC19 strain, cells that were spread on LB-amp 
plates could not grow any more. This indicated, that the pUC19 plasmid was lost, 
because of an overexpression of RNAI and the resulting inhibition of plasmid 
replication. Concerning the pUC19ΔRNAI plasmid it seemed that this plasmid was 
not propagated stably. Just a few colonies were still able to grow on the LB-amp 
plates indicating, that nearly all of the cells had lost their pUC19ΔRNAI plasmid. The 
induction of RNAI expression in the HMS174(DE3)::TN7<CAT-T7-
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RNAI>pUC19∆RNAI strain did result in the complete loss of the plasmid as no 
colonies were able to grow anymore on the ampicillin agar plates.  
 
4.1.1.6 Determination of pDNA concentration 
The different E.coli strains were grown over night in 5 ml LB-medium with and without 
100 µM IPTG. The next day, OD600 was measured and normalized cell numbers were 
pelleted. Plasmid DNA was extracted from the cell pellets and the DNA was eluted in 
50 µl elution buffer. By using the Nanophotometer, the concentrations of the 
extracted plasmid DNA were determined (table 4.4.). In order to confirm and to 
visualize the measured concentration values, 2 µl of extracted plasmids were loaded 
onto an agarose gel. A picture of the gel is shown in figure 4.3.  
 
Table 4. 4: Concentration of extracted plasmid DNA after induced and uninduced cell growth in LB-
medium.  
Host/Vector pair pDNA yield 
HMS174(DE3)+pUC19 138 ng/µl 
HMS174(DE3)+pUC19+IPTG 136 ng/µl 
HMS174(DE3)::TN7<T7-RNAI>pUC19 33 ng/µl 
HMS174(DE3)::TN7<T7-RNAI>pUC19+IPTG 27 ng/µl 
HMS174(DE3)+pUC19ΔRNAI 43 ng/µl 
HMS174(DE3)+pUC19ΔRNAI+IPTG 41 ng/µl 
HMS174(DE3)::TN7<T7-RNAI>pUC19ΔRNAI 35 ng/µl 
HMS174(DE3)::TN7<T7-RNAI>pUC19ΔRNAI+IPTG 17 ng/µl 
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The results of the plasmid preparation assay showed clearly, that the pUC19 plasmid 
is much more stable in the HMS174(DE3) strain than the pUC19ΔRNAI plasmid. 
Only approximately a third of the amount of plasmid DNA was extracted from the 
HMS174(DE3)+pUC19ΔRNAI when compared to the HMS174(DE3)+pUC19 strain. It 
could be further shown that IPTG per se had no influence on plasmid concentration, 
as the addition of IPTG to the RNAI-free strains did not change plasmid 
concentration. Concerning the HMS174(DE3) strains, where RNAI was integrated 
into the genome, plasmid concentration decreased dramatically. As the T7-system is 
a very leaky one, sufficient RNAI seemed to be produced for replication inhibition 
even in the absence of IPTG. The addition of IPTG led to only a further slight 
Fig.4 3: Extracted plasmid DNA after growth in LB-medium with 
and without IPTG. 2 µl of extracted plasmids were loaded onto an 
agarose gel. Plasmids extracted from control cells not carrying the 
T7-RNAI fragment in their chromosome are highlighted in green 
whereas plasmids extracted from cells carrying the T7-RNAI 
fragment are pointed out in red.  
 
 52 
decrease in plasmid concentration. With these experiments, a clear “proof of 
concept” was demonstrated.  
As it was shown that a down regulation of plasmid replication could be achieved by 
an over expression of RNAI, the next step was to make the expression of RNAI 
tightly controllable. This was done by changing the T7-promoter to a repressible, 
phagal pLlacO-1 promoter as described in the next chapter.  
 
 
4.1.2 Regulation of plasmid copy number via inducible expression of 
RNAI under control of the pLlacO-1 promoter 
 
In order to be able to regulate RNAI expression, the pBSK::TN7<CAT-T7-RNAI> 
vector was modified and the T7 promoter was substituted with the pLlacO-1 promoter. 
The modified plasmid was transformed into a JM109 strain because this strain 
already owned the lac-repressor (lacIq). The effect of IPTG on plasmid replication 
was investigated by plasmid preparation assays.  
In a next step the linear pLlacO-1-RNAI fragment was integrated into the genome of 
JM109. The influence of RNAI overexpression on the plasmids pUC19, pUC19ΔRNAI 
and pBR322 in the JM109 strain was investigated. Plasmid preparation assays were 
carried out and the PCN per cell was determined by using the Bioanalyzer.  
 
4.1.2.1 Construction of the pBSK::TN7<CAT-pLlacO-1-RNAI> vector 
The pBSK::TN7<CAT-T7-RNAI> vector carrying the RNAI gene under the control of 
the T7 promoter was digested with the enzymes PstI and NcoI. With this enzymatic 
restriction, a fragment was cut out of the vector constituting the T7-RNAI part of the 
vector.  
 
In order to separate the vector backbone from the DNA fragment, the restriction 
reaction mix was loaded onto a preparative agarose gel. The fragment was cut out 
from the gel and the DNA was purified according to section 3.3.4. This fragment was 
used in the next step as PCR template. For this PCR, the Phusion polymerase was 
used together with primers proms_RNAI_for, which carried a XhoI restriction site, and 
the primer placO_back, which carried a BlpI restriction site. With this PCR reaction, a 
linear DNA fragment was constructed, with the RNAI gene under the control of the 
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pLlacO-1 promoter. In order to substitute the T7-RNAI fragment with the pLlacO-1-RNAI 
fragment, the pBSK::TN7<CAT-T7-RNAI> vector, as well as the pLlacO-1-RNAI 
fragment were cut with the enzymes XhoI and BlpI. As both enzymes produce sticky 
ends at defined restriction sites, a directed ligation could be carried out where the 
pLlacO-1-RNAI fragment was ligated into the linearized pBSK::TN7 vector (figure 4.4.). 
The DNA of the ligation mix was precipitated with isopropanol and the pLlacO-1-RNAI 
plasmid was electrotransformed into competent NEB10ß cells. Cells were plated onto 
LB-cm agar plates and incubated over night at 37°C. Growing cells were screened 
using the primers placO_back and TN7/2-HO-for and plasmids were sequenced.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4 4: pBSK::TN7<CAT-pLlacO-1-RNAI> 
plasmid. The T7 promoter was therefore 
substituted by PCR with the pLlacO-1 
promoter. 
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a) 
b) 
4.1.2.2 Impact of IPTG induction on replication of pBSK::TN7<CAT-pLlacO-1-
RNAI> plasmid 
The pBSK::TN7<CAT-pLlacO-1-RNAI> plasmid was purified using a Miniprep kit and 
transferred into competent JM109 cells by electroporation. After electroporation cells 
were plated onto LB-cm agar plates and incubated over night at 37°C. The next day, 
colonies were picked from the plate and 10 ml of LB-cm medium with and without 
IPTG were inoculated. OD600 of these cell cultures was measured the next day and 
plasmid preparation assays were performed. Therefore, same cell numbers were 
pelleted and the plasmids were extracted from the cell pellets according to the 
manufactures instructions. The eluted plasmid DNA was measured using the 
Nanophotometer and 2 µl of each plasmid solution were loaded onto an agarose gel. 
The same procedure was carried out with an over night culture grown in LB-cm 
medium that was diluted 1:100 the next day and freshly induced with IPTG. After 5 
hours of induced growth, minipreps with same cell numbers were carried out and the 
extracted plasmid concentration was again determined by the Nanophotometer and 
by loading 2 µl of plasmid solution onto an agarose gel. Measured values as well as 
the gel photo are depicted in figure 4.5.  
 
JM109+pBSK::TN7<CAT-pLlacO-1-
RNAI>  
on 5h 
uninduced 83 ng/µl 71,5 ng/µl 
induced with 100µM IPTG 178 ng/µl 76,5 ng/µl 
 
 
 
 
 
 
 
 
 
 
 
 
 
JM109+pBSK::TN7<CAT-pLlacO-1-RNAI> 
Fig.4 5: Plasmid concentration of JM109 hosting the 
pBSK::TN7<CAT-pLlacO-1-RNAI> plasmid. (a) Cells were 
grown in LB-medium with and without IPTG for 5 hours 
and over night. Plasmids were isolated according to a 
Miniprep Kit and concentrations were measured. (b) 2 µl 
of each plasmid solution were loaded onto an agarose 
gel. 
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Surprisingly, the results of the plasmid preparation assay showed that the induction 
of RNAI expression by IPTG led to an increased concentration of plasmid DNA. This 
was true for plasmid preparations after 5 hours as well as for those from the 
overnight cultures. The expression of RNAI might have a controversial effect in this 
case. On the one hand it inhibits replication and thereby decreases plasmid 
concentration by binding to the primer RNAII. But as the pBSK::TN7<CAT-pLlacO-1-
RNAI> vector is a high copy number plasmid, the reduced replication may 
simultaneously lead to a greater stability of the plasmid. Fewer plasmid molecules get 
lost during cell division. Although there are lower numbers of plasmid DNA in one 
JM109 cell, more cells of the population still own the pBSK::TN7<CAT-pLlacO-1-RNAI> 
vector, finally resulting in an increase in the total amount of plasmid DNA.  
4.1.2.3 Integration of pLlacO-1-RNAI fragment into JM109 genome 
In order to investigate the effect of RNAI expression from a chromosomal copy of the 
RNAI gene, a linear pLlacO-1-RNAI fragment was constructed and integrated into the 
JM109 genome by using the pRED/ET plasmid.  
 
The linear pLlacO-1-RNAI fragment was obtained using PCR with the Phusion DNA 
polymerase and the primers TN7/2-HO-for for and TN7/2-HO-long-back. The 
emerging fragment (figure 4.6.) was purified from the PCR mix according to the 
Qiagen QIAEXII Kit. 
 
 
 
 
 
 
 
For integrating the linear DNA fragment into the genome of JM109, the Red/ET Kit 
from Gene Bridges was used as described in section 3.4.1.2. Therefore competent 
JM109 cells were transformed with the pRED/ET plasmid. These cells were then 
made competent and 400 ng of the linear pLlacO-1-RNAI fragment were added to 40 µl 
of JM109 cells by electroporation. Cells were plated on LB-cm agar plates and 
incubated over night at 37°C. Growing colonies were used for shake flask 
experiments. 
Fig.4 6: Linear pLlacO-1-RNAI fragment consisting of the RNAI gene under the control of the 
pLlacO-1 promoter and a chloramphenicol resistance gene. The fragment is flanked by 
homologous sequences (indicated by dark blue bars) necessary for the later integration into the 
JM109 genome 
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4.1.2.4 Bacterial growth under induced and uninduced conditions 
In order to check the impact of RNAI expression on plasmid copy number, 
JM109::TN7<CAT-pLlacO-1-RNAI> cells were made competent and transformed with 
the plasmids pUC19, pUC19∆RNAI and pBR322. Over night cultures were inoculated 
in LB-cm medium with and without IPTG. The next day, OD600 was measured and 
over night cultures, grown without IPTG, were adjusted to the same OD600 value by 
diluting them with fresh medium with and without IPTG and grown at 37°. Cell growth 
was observed by measuring OD600 hourly (table 4.5.).  
 
Table 4. 5.: Bacterial cell growth of different JM109 strains with and without IPTG 
Host/Vector pair o/n 2h 3h 4h 
JM109+pUC19 2,610 0,535 1,040 1,397 
JM109+pUC19+IPTG 1,860 0,518 0,987 0,936 
JM109::TN7<CAT-pLlacO-1-
RNAI>+pUC19 
2,2 0,522 1,239 1,470 
JM109::TN7<CAT-pLlacO-1-
RNAI>+pUC19+IPTG 
1,240 0,485 0,759 1,084 
JM109::TN7<CAT-pLlacO-1-
RNAI>+pBR322* 
2,630 0,526 0,952 1,567 
JM109::TN7<CAT-pLlacO-1-
RNAI>+pBR322+IPTG 
2,495 0,565 0,985 1,507 
JM109+pUC19ΔRNAI 2,630 0,745 0,936 1,122 
JM109+pUC19ΔRNAI+IPTG 1,735 0,803 0,107 1,396 
JM109::TN7<CAT-pLlacO-1-
RNAI>+pUC19ΔRNAI 
2,145 0,289 0,464 0,711 
JM109::TN7<CAT-pLlacO-1-
RNAI>+pUC19ΔRNAI+IPTG 
1,815 0,270 0,414 0,611 
*As there was no difference in plasmid concentration or cell growth between the 
induced (+IPTG) and the uninduced (without IPTG) state, controls were disregarded 
in the case of JM109::TN7<CAT-pLlacO-1-RNAI>+pBR322.  
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Comparison of the different OD600 values showed that there were no big differences 
in cell growth between the JM109::TN7<CAT-pLlacO-1-RNAI> strains and their 
controls. In every case, the addition of IPTG led to a slower cell growth. Concerning 
the pUC19 and the pUC19∆RNAI hosting cells, grown over night with IPTG, the 
OD600 value was even only half of that measured for uninduced cells. The  
addition of IPTG to JM109::TN7<CAT-pLlacO-1-RNAI>+pBR322 cells had nearly no 
effect on cell growth.   
 
4.1.2.5 Determination of pDNA concentration by plasmid preparation assays 
For the quantification of plasmid concentration, same cell numbers were pelleted and 
plasmid preparations were carried out according to the manufactures instructions. 
Plasmid concentrations were determined by the Nanophotometer and by loading of 2 
µl of plasmid DNA onto an agarose gel (fig. 4.7.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
JM109::TN7<CAT-
pLlacO-1-RNAI> 
pDNA yield 
+pUC19 89 ng/µl 
+pUC19+IPTG 71 ng/µl 
+pUC19ΔRNAI 198 ng/µl 
+pUC19ΔRNAI+IPTG 59 ng/µl 
JM109 (control)   
+pUC19 102 ng/µl 
+pUC19+IPTG 115 ng/µl 
+ΔRNAI 107 ng/µl 
+ΔRNAI +IPTG 119 ng/µl 
Fig.4 7: Extracted plasmid DNA after cell growth in LB / LB-cm medium, with and without IPTG. 
Plasmid concentrations were determined by using the Nanophotometer and by loading of 2 µl of 
plasmid DNA onto an agarose gel. Plasmids extracted from control cells not carrying the pLlacO-1-
RNAI fragment in their chromosome are highlighted in green whereas plasmids extracted from cells 
carrying the pLlacO-1-RNAI fragment are pointed out in red.  
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Irrespective of pBR322 hosting cells, the expression of RNAI, induced by IPTG 
addition, led to a reduction of plasmid concentration. Especially, the impact on the 
pUC19∆RNAI plasmid was rather impressing. Plasmid concentration was reduced 
about approximately two third when RNAI was expressed. In contrast to the T7 
promoter, the pLlacO-1 promoter could be tightly regulated, and RNAI expression was 
only achieved in the presence of IPTG. As the controls showed very clearly, both 
plasmids, pUC19 and pUC19∆RNAI, were stable in the JM109 cells in the presence 
and absence of IPTG.  
With these results, the hypothesis that RNAI leads to a reduction of plasmid 
concentration by inhibiting RNAII, was clearly confirmed. In the next step, the plasmid 
copy number per cell was determined by the Agilent 2100 expert bioanalyzer. 
 
4.1.2.6 Determination of PCN by Agilent 2100 expert bioanalyzer 
For the calculation of the plasmid copy number per cell, two parameters had to be 
determined in advance; the dried biomass and the total amount of DNA. 10 ml of the 
over night cultures, listed in table 4.6., were used for the determination of the 
biomass dry matter (BDM).  
 
Table 4.6.: Dried biomass from 10 ml of cell suspension 
JM109 dried biomass (mg) 
+pUC19 10,7 
+pUC19+IPTG 9,6 
+pUC19∆RNAI 10,6 
+pUC19∆RNAI+IPTG 9,1 
JM109::TN7<CAT-
pLlacO-1-RNAI> 
 
+pUC19 10,5 
+pUC19+IPTG 8,6 
+pUC19∆RNAI 10,8 
+pUC19∆RNAI+IPTG 11,1 
 
 
The amount of total DNA was determined by fluorimetric measurement. The standard 
curve was obtained by the dilution of calve thymus DNA. 
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Samples were prepared for the bioanalyzer as described in section 3.5.1. and loaded 
to the chip. 
The results of the dried biomass and the total amount of DNA were combined with 
those obtained by the bioanalyzer and the plasmid copy number per cell was 
calculated and is depicted in the diagrams below (figure 4.8.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results obtained by the bioanalyzer clearly showed that the plasmid copy number 
per cell of both plasmids (pUC19 and pUC19∆RNAI) did decrease in the presence of 
RNAI. Whereas the PCN of the pUC19 plasmid was decreased from 800 to 300 
Fig. 4.8.:. 
Fig.4 8: PCN/cell calculated by using the Agilenta 2100 expert bioanalyzer. PCNs were 
determined for the strains JM109+pUC19, JM109::TN7<CAT-pLlacO-1-RNAI>pUC19,, 
JM109+pUC19∆RNAI and JM109::TN7<CAT-pLlacO-1-RNAI>pUC19∆RNAI grown in LB / LB-cm 
with (pink column) and without (blue column) IPTG. 
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plasmids/cell, the PCN of the pUC19∆RNAI plasmid was even reduced about 900 
plasmids/cell. When RNAI was present in the host genome, PCNs of pUC19 as well 
as of pUC19∆RNAI were higher even in the absence of IPTG when compared to cells 
without RNAI in their genome. This might be due to a slight basal activity of the 
pLlacO-1 promoter, leading to low levels of RNAI inside the cell. As both plasmids are 
high copy number plasmids, these low levels of RNAI may have a stabilizing effect 
leading to a slight increase in PCN. The PCN of the pUC19∆RNAI plasmid in strain 
JM109::TN7<CAT-pLlacO-1-RNAI> was thereby 1000 compared to the pUC19 plasmid 
with a PCN of 800. As the pUC19∆RNAI plasmid itself does not produce any RNAI, 
the stabilizing effect of low basal transcription levels of the integrated copy of RNAI 
might be even more impressive resulting in this high PCN per cell.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 61 
4.2 Up regulation of plasmid copy number via inducible expression 
of uncharged tRNAs 
 
For the proper charging of a tRNA with its corresponding amino acid an enzyme 
called aminoacyl-tRNA synthetase is necessary. Regarding the E. coli alanyl-tRNA 
synthetase, the tRNAAla acceptor stem is sufficient for the right recognition (38). 
In the following experiments a vector was designed, carrying the tRNAAla gene under 
the control of the T7 promoter. The sequence of the tRNAAla was thereby mutated 
twice in order to inhibit proper charging with alanin (fig. 4.9.). Based on this tRNAAla 
vector a linear DNA fragment was amplified for the integration into the MG1655 
genome. Via P1 transduction the T7-tRNA fragment was transferred into the 
HMS174(DE3) chromosome, the JM108 chromosome and into the DH5α(DE3) 
chromosome by homologous recombination.  
 
 
 
 
 
 
 
 
 
The strains were transformed with the plasmids pUC19 and pBR322 by 
electroporation and shake flask experiments, for determining the impact of tRNA 
overexpression, were conducted. 
 
4.2.1 Construction of MCS-vector 
 
Using PCR the pBSK::TN7<CAT-T7-GFP> vector was modified to contain a Multiple 
Cloning Site (MCS) instead of the GFP gene. By using the 
MCS_TN7_GFP_1500bp_for and MCS_TN7_GFP_2435bp_back primer together 
with the Phusion DNA Polymerase, a linearized vector was produced with both ends 
consisting of parts of a multiple cloning site. The linearized vector was loaded onto a 
gel and purified using a gel extraction Kit. The purified fragment was later on treated 
Fig.4 9: Wt- and mutated tRNAAla. The two point mutations (blue) were incorporated by oligonucleotide 
synthesis and responsible for the presence of uncharged tRNAs (picture taken from Mairhofer et al., 
unpublished).  
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with the enzymes BamHI, encoded on both primers, and DpnI to get rid of template 
contaminations. The fragment was ligated afterwards, giving rise to the circular 
pBSK::TN7<CAT-MCS> as shown in figure 4.10. This vector was used in a later step 
for inserting the tRNA fragment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Competent NEB10ß cells were transformed with the vector by electroporation and 
cells were plated on LB-cm agar plates. As control, the linearized vector was also 
transferred into the cells, to check for template carry-over. The next day, growing 
colonies were picked and inoculated in LB-medium. Plasmids were extracted by a 
miniprep Kit and a control digestion was done using the restriction enzyme HindIII. In 
the case of the pBSK::TN7<CAT-MCS> vector, the linearized plasmid should appear 
on the gel with a length of 4650 bp. Vector sequence was verified by sequencing.  
 
4.2.2 Construction of T7-tRNA plasmid 
 
The T7-tRNAmut fragment was obtained by annealing the two oligonucleotides Xho-
pT7-AlaU-back (carried the T7-promoter) and BglII-tRNA-AlaU-for (carried the tRNA 
sequence). Therefore, the oligos were mixed in equal amounts and cooled down 
slowly from 99°C to 36°C. During this drop of temperature, the oligos bound due to 
Fig.4 10: pBSK vector carrying a multiple cloning site 
(MCS). For MCS insertion, a PCR was carried out with 
the primers MCS _TN7_GFP_1500bp_for and 
MCS_TN7_GFP_2435bp_back.  
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their homologous sequences. Using the Klenow polymerase the remaining single 
strand ends were filled up with nucleotides and the double stranded T7-tRNAmut 
fragment was obtained. As the two oligos carried a defined restriction site, the 
fragment, as well as the pBSK::TN7<CAT-MCS> vector, were cut with the restriction 
enzymes BglII and XhoI. Vector and fragment were purified from the restriction 
reaction and were ligated afterwards. Competent DH10ß cells were transformed with 
the pBSK::TN7<CAT-T7-tRNAmut> by electroporation and cells were plated on LB-cm 
agar plates. Plasmids were extracted from the growing colonies and a control 
restriction was carried out by using the enzyme BseYI. In the case of a positive 
result, two fragments, ~1000 bp and ~3733 bp long, should be obtained. As these 
fragments were actually visible on an agarose gel, plasmids were sequenced. In this 
way, the pBSK::TN7<CAT-T7-tRNAmut> plasmid, depicted in figure 4.11. was 
constructed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.3 Construction of linear T7-tRNAmut fragment for homologous 
recombination into E. coli chromosome 
 
The T7-tRNA plasmid was extracted from DH10ß cells and the T7-tRNAmut fragment 
was cut out of the vector using the enzymes KpnI and SacI. The obtained fragment 
did carry a chloramphenicol resistance gene, the tRNA gene under the control of the 
Fig.4 11: pBSK::TN7<CAT-T7-tRNAmut> 
plasmid obtained by cloning the annealed 
T7- and tRNAmut- oligonucleotides into the 
MCS of the pBSK::TN7<CAT-MCS> 
vector.  
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T7 promoter and was flanked by homologous sequences (figure 4.12.). The fragment 
was purified from the restriction mix and competent MG1655 cells carrying the 
pKD46 plasmid were transformed with 300 ng of the linear fragment. 
 
 
 
 
 
 
 
 
 
Cells were plated on LB-cm agar plates. Growing colonies were screened with 
plasmid ori primers (RNAII 115 back, RNAII 625 for) on the one hand and primers 
that bound to the cm-resistance gene (cat begin for) and in the MG1655 genome 
(TN7/2-HO-for) on the other hand. Positive colonies were cured from the pKD46 
plasmid by placing them to 42°C. The T7-tRNAmut fragment was amplified in a PCR 
from the MG1655 genome by using the primers cat begin for and TN7/2 extern. The 
obtained product was sequenced to check for integrity of the T7-tRNAmut expression 
element.  
 
 
4.2.4 Integration of T7-tRNAmut fragment into HMS(174)DE3 genome 
 
In the next step, a P1 phage transduction was carried out and the T7-tRNAmut 
fragment was integrated into the HMS174(DE3) genome by homologous 
recombination. Growing colonies were screened with the primers cat begin for and 
TN7/2 extern and the amplified fragments were sequenced. Using this approach 
HMS174(DE3)::TN7<CAT-T7-tRNAmut> cells were obtained.  
 
4.2.4.1 Shake flask experiments and determination of plasmid concentration 
In order to investigate the effect of tRNA overexpression on plasmid concentration, 
cells of the HMS174(DE3)::TN7<CAT-T7-tRNAmut> strain were made competent and 
transformed with the pUC19 plasmid by electroporation. 10 ml of LB-cm medium with 
Fig.4 12: T7-tRNA fragment for integration into MG1655 genome. The fragment was transferred to a 
HMS(DE3)174 strain by P1 transduction and inserted into it’s chromosome via homologous 
recombination. Homologous sequences are indicated by dark blue bars. 
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and without IPTG were inoculated with HMS174(DE3)::TN7<CAT-T7-
tRNAmut>+pUC19 cells. As control, HMS174(DE3)+pUC19 were also grown induced 
and uninduced over night. The next day, same cell numbers were centrifuged and 
plasmids were extracted from the cell pellets. Additionally, uninduced over night 
cultures were diluted 1:100 and induced again with 100 µM IPTG. After 4 hours of 
growth at 37°C shaking, plasmids from equal amounts of cells were extracted again. 
Plasmid concentrations were measured by the Nanophotometer and 2 µl of the 
eluted plasmids were loaded onto an agarose gel (figure 4.13.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4 13.: Concentrations of extracted plasmid DNA after over night cell growth and 4 hours of 
growth in LB-cm medium and in LB-cm medium supplied with 100 µM IPTG. Plasmid 
concentrations were determined by the Nanophotometer and by loading of 2 µl of eluted 
plasmids onto an agarose gel. Plasmids extracted from control cells not carrying the T7-
tRNAmut fragment in their chromosome are highlighted in green whereas plasmids extracted 
from cells carrying the T7-tRNAmut fragment are pointed out in red.  
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Surprisingly, the results showed the very opposite of the expected effect. The over 
expression of uncharged tRNAs led to a massive decrease in plasmid concentration 
instead of increasing it. This phenomenon was observed in both cases, after 4 hours 
of cell growth as well as after over night growth. The strong reduction of plasmid 
concentration might be caused by the activation of the stringent response, as the 
strain used in this experiment is a relA+ one. The stringent response possibly leads to 
a down regulation of RNAI and RNAII expression which in turn is responsible for the 
inhibition of plasmid replication. Further, it was again clearly apparent, that the T7-
system is a very leaky one. Even in the absence of IPTG, tRNA expression seemed 
to be induced and nearly no difference in plasmid concentration could be detected 
between the induced and the uninduced state. When the tRNA producing cells were 
inspected under the microscope, cells showed a phenotype that is normally observed 
under starvation like conditions. Instead of being short and rod shaped, cells were 
very long and filamentous. 
 
4.2.5 Integration of T7-tRNAmut fragment into genome of relA- strains 
 
4.2.5.1 Shake flask experiments and determination of plasmid concentration 
It was reported that up regulation of plasmid copy number by the action of tRNAs, 
might not be that efficient in relA+ E. coli strains .As this was the case for the 
HMS174(DE3) strain used, all experimental set up was repeated with the relA mutant 
strains DH5α(DE3) and a JM108(DE3).  
Therefore the two new strains were made competent and transformed with the 
pTSA29 plasmid by electroporation. Cells were infected with the already existing P1 
phage lysate, and the T7-tRNAmut was integrated in their chromosome by 
homologous recombination. The tRNA-containing strains were transformed in the 
next step with the plasmids pUC19 and with the low copy number plasmid pBR322. 
Cells of both strains, as well as controls, consisting of cells only carrying the plasmids 
but not the tRNA copy in their chromosome, were grown in LB-cm medium, with and 
without IPTG over night. The next day, OD600 was measured and same cell numbers 
were centrifuged. Plasmids were extracted from cell pellets and plasmid 
concentration was determined by the Nanophotometer and by loading 2 µl of the 
eluted plasmids onto an agarose gel (fig. 4.14.).  
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 Minipreps 
o.n. 
 Minipreps 
o.n. 
DH5α(DE3)+pBR322 51,5 ng/µl JM108(DE3)+pBR322 50 ng/µl 
DH5α(DE3)+pBR322+IPTG 36,5 ng/µl JM108(DE3)+pBR322+IPTG 49 ng/µl 
DH5α(DE3)::TN7<T7-
tRNAmut>+pBR322 
55 ng/µl JM108(DE3)-T7-tRNA+pBR322 38 ng/µl  
DH5α(DE3)::TN7<T7-
tRNAmut>+pBR322+IPTG 
35 ng/µl JM108(DE3)-T7-tRNA+pBR322+IPTG 35 ng/µl 
DH5α(DE3)+pUC19 71 ng/µl JM108(DE3)+pUC19 112 ng/µl 
DH5α(DE3)+pUC19+IPTG 77,5 ng/µl JM108(DE3)+pUC19+IPTG 97 ng/µl 
DH5α(DE3)::TN7<T7-
tRNAmut>+pUC19 
75,5 ng/µl JM108(DE3)-T7-tRNA+pUC19 68 ng/µl 
DH5α(DE3)::TN7<T7-
tRNAmut>+pUC19+IPTG 
76,5 ng/µl JM108(DE3)-T7-tRNA+pUC19+IPTG 66 ng/µl 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In general one could say, that plasmid concentrations were rather unaffected by 
tRNA expression. Concerning the DH5α(DE3)-strain, this was true for both plasmids, 
the pBR322 and the pUC19. In the case of JM108(DE3), plasmid concentration was 
slightly reduced regarding the pBR322 plasmid. The effect of tRNA expression in this 
strain on the pUC19 plasmid was more impressive, as plasmid concentration was 
Fig.4 14.: Plasmid concentrations of listed strains, determined by using the 
Nanophotometer and by loading 2 µl of eluted plasmids onto an agarose gel. 
Plasmids were extracted from cells that were grown in LB-cm / LB medium, with 
and without IPTG over night.  
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decreased about approximately 40 ng/µl. The same effect was observed before in 
the HMS174(DE3) strain.  
For all the experiments described above, a mutated form of the tRNA gene was used. 
This mutation included two point mutations as pictured in fig. 4.9. These mutations 
should inhibit the efficient charging of the tRNA with its corresponding amino acid. At 
the same time it is possible, that due to the alteration of the tRNA sequence, the 
enzymatic cleavage of the bound RNAI was disturbed since the accurate mechanism 
has not been elucidated yet. The original sequence might be important for the proper 
action of tRNAs as nucleases.  
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5 Conclusion and Outlook 
 
The idea of using plasmid DNA for the treatment of genetic disorders and for the 
development of vaccines has become a major issue for the pharmaceutical industry. 
As more and more DNA-based drugs have already reached phase III of clinical trials 
or even are available on the market, there is a steadily increasing demand for high 
quality pDNA. 
A big problem of excessive plasmid production is the high metabolic load that is 
exerted on the host cell by sole plasmid replication, leading to a decrease in growth 
rate and biomass yield and finally to decreased overall pDNA yield.  
 
The main goal of this work was to develop a system that allows for the control of 
plasmid replication in E.coli, and therefore enables the decrease of metabolic load. 
By the insertion of a chromosomal copy of the RNAI gene under the control of the 
pLlacO-1 promoter the major objective of the current studies was fulfilled, since PCN 
could be decreased by addition of the inducer IPTG. It was shown in shake flask 
experiments, that the developed regulation system allows precise and impressive 
downregulation of PCN of ColE1-type plasmids by RNAI overexpression. As a 
successful application of this system was already proved in a small experimental set 
up, a large scale feasibility study, employing fed batch fermentations, has to be 
conducted in the near future. By the use of this regulation mechanism, it will be 
possible to keep the metabolic burden on the host cell low at the beginning of the 
bioprocess. Once biomass has accumulated, downregulation of the PCN can be 
stopped since a metabolizable inducer (e.g. lactose) is used and excessive 
production of pDNA is induced in the absence of the inducer. 
Additionally, the feasibility of another extra high copy variant of the ColE1 ori could be 
shown. By chromosomal complementation of the ∆RNAI mutation of pUC19∆RNAI by 
TN7<CAT-pLlacO-1-RNAI> the pUC19∆RNAI plasmid could be stabilized and it is 
therefore anticipated that higher pDNA yields are possible using this novel ori. 
Another interesting approach of this work was the active upregulation of PCN by the 
overexpression of uncharged tRNAs. As already published, interaction of uncharged 
tRNAs with RNAI should result in an increase in plasmid replication initiation, since 
RNAI is degraded. Contrarily, the opposite effect was observed throughout these 
studies. Massive downregulation of PCN, was achieved in relA+ strains. In the case 
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of relA- cells, PCN was unaffected by tRNA overexpression. As tRNAs used in these 
experiments did carry two point mutations to inhibit tRNA charging, it is possible that 
the RNAI-degrading activity of the tRNAs was disturbed thereby. Repetition of 
experiments with wt tRNAs might bring the expected results and lead to an increase 
in plasmid replication initiation. 
 
Consequently, it could be shown that negative regulation of PCN is possible, by the 
overexpression of RNAI from a chromosomal gene copy. Tight regulation of RNAI 
expression can thereby be achieved by the use of the pLlacO-1 promoter. This newly 
developed regulation system might lead to a dramatic increase in the amount of 
pDNA yield during the fermentation process.  
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7 Appendix 
 
Primersequences: 
Sma_tetR_TN10_back TCCcccgggCCAATGCGATCTTTGTCGAAC 
XhoI_pT7_AlaU_ORG_back 
ccgCTCGAGgtagtTaatacgactcactataGGGGCTATAGCTCAG 
CTGGGAGAGCGC 
BglII_tAlaU_ORG_for 
GGAagatctTGGTGgAGCTATGCGGGATCGAACCGCAGACC 
TCCTG 
CGTGCAAAGCaggcgctctcccagctgagcta 
tRNA_seq_primer GTTGTATGTCTTCGCCGATC 
Xba_CAT_back gcTCTAGAagccactggagcacctc 
XbaI_rrnBT12_for_new ggTCTAGAaaaaggccatccgtcagg 
SpeI_rrnBT12_back_new gcACTAGTataaaacgaaaggctcagtc 
Xba_rrnBT12_back_new ggTCTAGAaaaaggccatccgtcagg 
SpeI_rrnBT12_for_new gcACTAGTataaaacgaaaggctcagtc 
pN25_part1 gcgcaacgcaattaatgtaagttagcgcgaATTGTCGAGGGA 
pN25_part2 TTCCTGAAAGCAAATaaattttttatgattTCCCTCGACAAT 
pN25_part3 ATTTGCTTTCAGGAAaatttttCTGTAtaatagattcataaa 
BsmBI_pN25_part4 
ATGATGcgtctcaTCATatttaaacTCTTCTctcaaaTTTATGAATCT 
ATTA 
SmaI_pN25_back tccCCCGGGgcgcaacgcaattaatgtaag 
SpeI_rrnBT12_back gACTAGTataaaacgaaaggctcagtcg 
XbaI_rrnBT12_for gcTCTAGAcatccgtcaggatggcc 
HindIII_lacIq_back cccAAGCTTgacaccatcgaatggtgc 
EcoRI_lacIq_for CCGgaattcTCACTGCCCGCTTTCCAG 
BsmBI_tetR_back GATGATcgtctctATGATGTCTAGATTAGATAAAAG 
BamHI_tetR_for GCTGCTggatccTTAAGACCCACTTTCACATTTAAG 
XhoI_proms_RNAI_for CCGctcgagAACAAAAAAACCACCGCTACC 
BlpI_pLtetO_back 
ATGATGgctaagcTCCCTATCAGTGATAGAGATTGACATCCCTAT 
CAGTGATAGAGATACTGAGCACacagtatttggtatctgcgc 
BlpI_placara_back 
GGAagatctTGGTGcAGCTATGCGGGATCGAACCGCAGACCTCC 
TGCGTGCAAAGCAGgcgctctcccagctgagctaTAGATT 
Cacagtatttggtatctgcgc 
BlpI_pLlacO_back 
ATGATGgctaagcATAAATGTGAGCGGATAACATTGACATTG 
TGAGCGGATAACAAGATACTGAGCAC 
acagtatttggtatctgcgc 
Xho_pT7_AlaU_back 
ccgCTCGAGTaatacgactcactataGcGGCTAtagctcagctgggag 
agcgcatctgcgc 
BglII_tRNA_AlaU_for 
GGAagatctTGGTGcAGCTATGCGGGATCGAACCGCAG 
ACCTCCTGCGTG 
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CAAAGCAGgcgctctcccagctgagcta 
MCS_TN7_GFP_1500bp_for gcgcGGATCCcGGGctcgagGCCACTGGAGCACCTCAAAAAC 
MCS_TN7_GFP_2435bp_back gatgGGATCCagatctTCTAGAgcatccatttattactcaaccg 
T7prom-RNAI 
TTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACC 
AAATACTGTCTATAGTGAGTCGTATTAAAGCTT 
T7term-RNAI 
GAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGTTGG 
TAGCGGTGGTTTTTTTGTTCTAGCATAACCCCTTGGGGC 
RNAI-10promΔback  CTACGGCATGTGATCTTGAACAGTATTTGGTATCTGCGC 
RNAI-35promΔfor  TTAGGCCACGTGAAGTTGAACTCTGTAGCACCGCCTAC 
m13-20 5‘ tgtaaaacgacggccagtg 3‘ 
TN7/2-HO-for 5‘ tga aga agt tcg cgc gcg 3‘ 
cat begin for 5‘ caacggtggtatatccagtg 3‘  
RNAII 115 back 5‘ TCTAGTGTAGCCGTAGTTAG 3‘ 
RNAII 652 for 5‘ GGTTATCCACAGAATCAGGG 3‘  
TN7/2 extern 5‘tggcgctaattgatgccg 3‘  
TN7/1-HO-long-back 5' gttgcgacggtggtacgc 3' 
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8 Abbreviations 
 
aa aminoacid 
amp ampicillin 
AmpR ampicillin resistance 
bp base pairs 
cfu colony forming unit 
cm chloramphenicol 
CmR chloramphenicol resistance 
DMSO dimethyl-sulfoxide 
DNA  desoxyribonucleic acid 
dNTPs nucleotide triphosphates 
E. coli Escherichia coli 
GFP Green Fluorescent Protein 
h hours 
IPTG isopropyl -D-thiogalactopyranoside 
kan kanamycin 
KanR kanamycin resistance 
kbp kilo base pairs 
min minutes 
mRNA messenger RNA 
OD600nm optical density at a wavelength of 600 nm 
Ori origin of replication 
PCN plasmid copy number 
PCR polymerase chain reaction 
pDNA plasmid DNA 
ppGpp guanosine tetraphosphate 
RNA ribonucleic acid 
ssDNA single stranded DNA 
tet tetracycline 
Tm melting temperature 
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